THE ROLE OF ENTEROCYTE FATTY ACID-BINDING PROTEINS IN THE INTESTINE AND WHOLE-BODY ENERGY HOMEOSTASIS

By

ATREJU IAN LACKEY

A dissertation submitted to the

School of Graduate Studies

Rutgers, The State University of New Jersey

In partial fulfillment of the requirements

For the degree of

Doctor of Philosophy

Graduate Program in Nutritional Sciences

Written under the direction of

Dr. Judith Storch

And approved by

______________________________________

______________________________________

______________________________________

______________________________________

______________________________________

New Brunswick, New Jersey

October, 2019
ABSTRACT OF THE DISSERTATION

The Role of Enterocyte Fatty Acid-Binding Proteins in the Intestine and Whole-Body Energy Homeostasis

By Atreju Ian Lackey

Dissertation Director:

Dr. Judith Storch

The fatty acid binding protein (FABP) family consists of 14-15 kDa cytoplasmic proteins which are abundantly expressed in various mammalian tissues. In the proximal small intestinal enterocyte, at least three FABPs are highly expressed: liver FABP (LFABP; FABP1), which is also expressed in the liver, intestinal FABP (IFABP; FABP2), which is only expressed in the small intestine, and cellular retinoid binding protein 2 (CRBP2), which is also only expressed in the small intestine. Previous studies in high fat (HF) fed mice null for either LFABP or IFABP revealed a divergent phenotype, with LFABP\textsuperscript{-/-} mice displaying a metabolically healthy obese (MHO) phenotype, while IFABP\textsuperscript{-/-} mice remained lean. Conditional knock out LFABP mice (LFABP\textsuperscript{-cKO}) were generated to assess what role intestinal-LFABP may have in the MHO phenotype. Like HF fed whole-body LFABP\textsuperscript{-/-} mice, intestine-specific LFABP\textsuperscript{-/-} (LFABP\textsuperscript{int/-}) were found to have better capacity for endurance exercise when compared to their wild-type (WT) “floxed” controls (LFABP\textsuperscript{fl/fl}). Additionally, female LFABP\textsuperscript{int/-} were found to be more obese after the HF feeding challenge, having greater BW gain and increased fat mass. Thus, the ablation of intestine-specific ablation of LFABP is enough to induce the MHO phenotype in female mice, and improved exercise capacity in male and female mice. To assess the intestinal phenotypic changes that might explain
their lean phenotype, HF feeding studies were performed in IFABP−/− mice. Additionally, as it was observed that HF fed IFABP−/− mice had a more fragile small intestine, we hypothesized that the ablation of IFABP may result in alterations in intestinal morphology and structure. IFABP−/− mice were found to have reduced energy absorption, taking in fewer calories while excreting the same amount of calories as their WT counterparts. Additionally, IFABP−/− mice had more rapid intestinal transit, partly explaining the reduction in energy absorption. IFABP−/− mice were observed to have a shortened average villus length, a thinner muscularis layer, reduced goblet cell density, and reduced Paneth cell abundance. The ablation of IFABP also resulted in alterations in tissue retinoid levels, and mucosal vitamin A-related gene expression. Although IFABP−/− mice were found to have a drastic reduction in mucosal CRBP2 gene expression, no changes were observed in CRBP2 protein abundance. Taken together, this work has demonstrated a role for enterocyte lipid binding proteins in efficient uptake and trafficking of not only dietary lipid, but nutrients in general. These studies have also revealed a role for the enterocyte FABPs in modulating intestinal physiology, intestinal morphology, and the whole-body ramifications of such alterations.
Acknowledgements

I would like to thank Dr. Judy Storch for being my graduate mentor. It has been a privilege to have had the opportunity to work in her lab, and her guidance has been integral to the development and execution of this work. I am also very grateful to the assistance and advice that I have consistently received from my committee members. I would like to thank Dr. Laurie Joseph for helpful advice, suggestions, and histological expertise that enabled me to develop this project. I would also like to thank Dr. Loredana Quadro, who’s enthusiastic and thought-provoking questions were integral to expanding my thinking regarding this work and the program. I would like to thank Dr. Malcolm Watford for helpful discussions on whole-body metabolism, and for always having an interesting story on hand to tell. I would also like to thank Dr. Michael Verzì for providing additional expertise in intestinal physiology, and for his thoughtful questions and suggestions, which have helped me throughout this process.

I have been fortunate to encounter many great people within the Storch laboratory during my time at Rutgers University. I would like to thank Yin Xiu Zhou for her expertise in animal surgery as well as her constant support. I would also like to thank Dr. Heli Xu for all of the advice and support that she has provided during the last 6 years. Heli started out the program at the same time as me, and quickly became one of my closest friends and colleagues during my time here. I would like to thank the other graduate students in the lab, Hiba Tawfeeq and Anastasia Diolintzi, who studied similar but different aspects relating to the FABP project. Our conversations along with their support and encouragement were helpful with this process. I would also like to thank the undergraduate students that I have had the opportunity to work with as a mentor. Cindy Li, Tina Chen, Justine Doran, and Sophia Zacharisen were all hardworking and dedicated students. Working with them taught me a lot as well, and I hope that the experience they had with the lab will help them with their future endeavors.
I would like to thank Dr. Ghassan Yehia from the Rutgers Genome Editing Core Facility, who’s expertise was integral for generating the LFABP-cKO mice.

I would like to thank the Nutritional Sciences Department and the Rutgers Center for Lipid Research. I would like to thank Dr. Tracy Anthony for always being open to conversation and questions, providing helpful advice, new ideas, and encouragement. I would also like to thank the students and staff that have been incredibly helpful during my time here including Dr. Bryn Sachdeo, Dr. Dylan Klein, Cheng Li, Maryam Honarbakhsh, PJ Wisniewski, Esther Mezhibovsky, Emily Mirek, William Jonsson, Gabby Wahler, Kevin McCarthy, DJ Polacik, and Laura Amador.

Finally, I would like to thank my family, friends, and Melanie Gampon. None of this would have been possible without their patience, kindness, and support.
# Table of Contents

Abstract .......................................................................................................................... ii

Acknowledgements ........................................................................................................ iv

List of Tables .................................................................................................................... ix

List of Figures .................................................................................................................. x

List of Abbreviations ...................................................................................................... xiii

<table>
<thead>
<tr>
<th>Chapter 1: Introduction and Review of the Literature</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Dietary Triglycerides</td>
<td>2</td>
</tr>
<tr>
<td>Digestion of Triglycerides</td>
<td>5</td>
</tr>
<tr>
<td>Small Intestine Composition and Structure</td>
<td>14</td>
</tr>
<tr>
<td>Enterocyte FA and MG Uptake</td>
<td>17</td>
</tr>
<tr>
<td>Intestinal Lipid Processing</td>
<td>19</td>
</tr>
<tr>
<td>Lipid Sensing and Signaling in the Intestine</td>
<td>22</td>
</tr>
<tr>
<td>Fatty Acid Binding Proteins</td>
<td>24</td>
</tr>
<tr>
<td>Enterocyte FABPs</td>
<td>26</td>
</tr>
<tr>
<td>LFABP</td>
<td>28</td>
</tr>
<tr>
<td>IFABP</td>
<td>29</td>
</tr>
<tr>
<td>LFABP and IFABP in Intestinal Lipid Metabolism</td>
<td>30</td>
</tr>
<tr>
<td>LFABP/-/- and IFABP/-/- Mice</td>
<td>33</td>
</tr>
<tr>
<td>Summary</td>
<td>34</td>
</tr>
<tr>
<td>Chapter 2: The Generation and Whole-Body Phenotyping of Intestine-Specific Liver Fatty Acid-Binding Protein Knockout Mice</td>
<td>36</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Abstract</td>
<td>37</td>
</tr>
<tr>
<td>Introduction</td>
<td>38</td>
</tr>
<tr>
<td>Experimental Procedures</td>
<td>42</td>
</tr>
<tr>
<td>Results</td>
<td>48</td>
</tr>
<tr>
<td>Discussion</td>
<td>59</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 3: Mechanisms Underlying Reduced Weight Gain in Intestinal Fatty Acid-Binding Protein (IFABP) Null Mice</th>
<th>64</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>65</td>
</tr>
<tr>
<td>Introduction</td>
<td>66</td>
</tr>
<tr>
<td>Experimental Procedures</td>
<td>68</td>
</tr>
<tr>
<td>Results</td>
<td>75</td>
</tr>
<tr>
<td>Discussion</td>
<td>93</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 4: General Conclusions and Future Directions</th>
<th>102</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Ablation of Intestinal LFABP Does Not Fully Recapitulate the MHO Phenotype</td>
<td>103</td>
</tr>
<tr>
<td>Alterations Specific to the Intestine Can Induce Dramatic Whole-Body Responses</td>
<td>105</td>
</tr>
<tr>
<td>The Ablation of IFABP Induces an Intestinal Fragility Phenotype</td>
<td>108</td>
</tr>
<tr>
<td>The Gastrointestinal Tract Plays a Large Role in Whole-body Responses to Nutrient Challenges</td>
<td>109</td>
</tr>
</tbody>
</table>
Appendix: 110

Abstract 111

Introduction 112

Experimental Procedures 113

Results 116

Discussion 125

Literature Cited 131
List of Tables

Chapter 1

| Table 1-1 | The tissue location for the expression of FABP family members. | 23 |

Chapter 3

| Table 3-1 | Primer sequences used for qPCR analyses. | 74 |

Appendix

| Table 1 | Summary of LF and HF gene expression analyses. | 124 |
### List of Figures

#### Chapter 1

| Figure 1-1 | LFABP and IFABP structure. | 4 |
| Figure 1-2 | Components and histological organization of gastrointestinal tract-related organs. | 8 |
| Figure 1-3 | Cells of the gastrointestinal tract that are present in the small intestine. | 11 |
| Figure 1-4 | Uptake and re-esterification of dietary FA and MG in the intestinal enterocyte. | 18 |
| Figure 1-5 | Small intestinal location of enterocyte FABPs | 25 |

#### Chapter 2

| Figure 2-1 | The generation of tissue specific knockout mice using the CRISPR/Cas and Cre/lox approach. | 41 |
| Figure 2-2 | Strategy used to generate LFABP-cKO mice. | 43 |
| Figure 2-3 | Confirmation of generation of LFABP^{fl/fl} and LFABP^{int/-} mice. | 50 |
| Figure 2-4 | Body weight, body weight gain, and fat mass for LFABP^{fl/fl} and LFABP^{int/-} mice after 12 weeks of 45% Kcal HF feeding. | 52 |
| Figure 2-5 | Body weight, body weight gain, and fat mass for LFABP^{fl/fl} and LFABP^{int/-} mice after 12 weeks of 45% Kcal HF feeding. | 54 |
| Figure 2-6 | Blood analyses for LFABP^{fl/fl} and LFABP^{int/-} mice after 12 weeks of 45% Kcal HF feeding. | 56 |
Figure 2-7 Analyses of spontaneous of activity and endurance capacity for LFABP$^{fl/fl}$ and LFABP$^{int/−}$ mice after 12 weeks of 45% Kcal HF feeding. 58

Chapter 3

Figure 3-1 Body weight and fat mass for WT and IFABP$^{−/−}$ mice after 12 weeks of 45% Kcal or 60% Kcal fat feeding. 76

Figure 3-2 mRNA expression and protein levels of proximal small intestine FABPs in WT and IFABP$^{−/−}$ mice after 12 weeks of 45% Kcal HFD. 77

Figure 3-3 Fecal lipid content, fat absorption localization, total fecal output, and intestinal transit times in WT and IFABP$^{−/−}$ mice after 12 weeks of HF feeding. 79

Figure 3-4 Average length of SI in WT and IFABP$^{−/−}$ mice that have been fed a 45% Kcal HFD for 12 weeks. 81

Figure 3-5 Small intestinal structure in 45% Kcal HF fed WT and IFABP$^{−/−}$ mice. 82

Figure 3-6 BrdU staining for 2h or 48h in the small intestinal crypts and villi of WT and IFABP$^{−/−}$ mice fed a 45% Kcal HFD for 12 weeks. 84

Figure 3-7 Assessments of intestinal permeability in WT and IFABP$^{−/−}$ mice fed a 45% Kcal HFD for 12 weeks. 86

Figure 3-8 Relative quantitation of mRNA expression of genes related to small intestinal structure and inflammation in 45% Kcal fat HF fed WT and IFABP$^{−/−}$ mice. 88

Figure 3-9 Assessment of small intestinal structure in 45% Kcal fat HF fed WT and IFABP$^{−/−}$ mice. 89
Figure 3-10  Assessment of small intestinal inflammation and ER stress in 45% Kcal fat HF fed WT and IFABP−/− mice.  90
Figure 3-11  Initial small intestinal phenotype assessments in 10% Kcal fat LF fed WT and IFABP−/− mice.  92

Appendix

Figure 1  Relative quantitation of small intestine mucosal mRNA expression of CRBP2 and other vitamin A-related genes in 45% Kcal fat HF fed WT and IFABP−/− mice.  117
Figure 2  Relative abundance of CRBP2 protein in 45% Kcal fat HF fed WT and IFABP−/− mice.  119
Figure 3  Tissue and plasma retinol and retinyl ester levels in 10% Kcal LF fed and 45% Kcal fat HF fed WT and IFABP−/− mice.  121
Figure 4  Relative quantitation of small intestine mucosa mRNA expression of CRBP2 and other vitamin A-related genes in 10% Kcal fat LF fed WT and IFABP−/− mice.  123
List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-AG</td>
<td>2-arachidinoylglycerol</td>
</tr>
<tr>
<td>5-HT</td>
<td>5-hydroxytryptamine</td>
</tr>
<tr>
<td>ACSL</td>
<td>Long chain acyl-CoA synthetase</td>
</tr>
<tr>
<td>AEA</td>
<td>Anandamide</td>
</tr>
<tr>
<td>AFABP</td>
<td>Adipocyte fatty acid binding protein</td>
</tr>
<tr>
<td>AJ</td>
<td>Adheren junction</td>
</tr>
<tr>
<td>ATF</td>
<td>Activating transcription factor</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>BBM</td>
<td>Brushborder membrane</td>
</tr>
<tr>
<td>BLM</td>
<td>Basolateral membrane</td>
</tr>
<tr>
<td>BrdU</td>
<td>Bromodeoxyuridine</td>
</tr>
<tr>
<td>BW</td>
<td>Body weight</td>
</tr>
<tr>
<td>Cas</td>
<td>CRISPR-associated</td>
</tr>
<tr>
<td>CB1R</td>
<td>Cannabinoid receptor 1</td>
</tr>
<tr>
<td>CBC</td>
<td>Crypt base columnar</td>
</tr>
<tr>
<td>CBR</td>
<td>Cannabinoid receptor</td>
</tr>
<tr>
<td>CCK</td>
<td>Cholecystokinin</td>
</tr>
<tr>
<td>CD36</td>
<td>Cluster of differentiation 36</td>
</tr>
<tr>
<td>CDH1</td>
<td>Cadherin 1</td>
</tr>
<tr>
<td>Chop</td>
<td>CCAAT-enhancer-binding protein homologous protein</td>
</tr>
<tr>
<td>cKO</td>
<td>Conditional knock out</td>
</tr>
<tr>
<td>CLDN</td>
<td>Claudin</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>COX</td>
<td>Cyclooxygenase</td>
</tr>
<tr>
<td>CRBP</td>
<td>Cellular retinol binding protein</td>
</tr>
<tr>
<td>CRBP2</td>
<td>Cellular retinol binding protein 2</td>
</tr>
<tr>
<td>CRISPR</td>
<td>Clustered regulatory interspaced short palindromic repeats</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>DG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>DGAT</td>
<td>Diacylglycerol acyltransferase</td>
</tr>
<tr>
<td>DIO</td>
<td>Diet induced obesity</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSB</td>
<td>Double strand breaks</td>
</tr>
<tr>
<td>EC</td>
<td>Endocannabinoid</td>
</tr>
<tr>
<td>ECS</td>
<td>Endocannabinoid system</td>
</tr>
<tr>
<td>eIF2</td>
<td>Eukaryotic initiation factor</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmic reticulum</td>
</tr>
<tr>
<td>FA</td>
<td>Fatty acid</td>
</tr>
<tr>
<td>FAAH</td>
<td>Fatty acid amide hydrolase</td>
</tr>
<tr>
<td>FABP</td>
<td>Fatty acid binding protein</td>
</tr>
<tr>
<td>FABPpm</td>
<td>Plasma membrane fatty acid binding protein</td>
</tr>
<tr>
<td>FAT</td>
<td>Fatty acid translocase</td>
</tr>
<tr>
<td>FATP</td>
<td>Fatty acid transport protein</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>GIP</td>
<td>Gastric inhibitory peptide</td>
</tr>
<tr>
<td>GLP</td>
<td>Glucagon-like peptide</td>
</tr>
</tbody>
</table>
GPAT  Glycerol-3-phosphate acyl transferase
GPCR  G-protein coupled receptor
GTT   Glucose tolerance test
H&E   hematoxylin and eosin
HF    High fat
HFABP Heart fatty acid binding protein
HFD   High fat diet
HNF   Hepatic nuclear factor
HPLC  High performance liquid chromatography
IFABP Intestinal fatty acid binding protein
IHC   Immunohistochemistry
ILBP  Ileal fatty acid binding protein
IMTG  Intramuscular triacylglycerol
iNOS  Inducible nitric oxide synthetase
JAMA  Junctional adhesion molecule A
KFABP Keratinocyte fatty acid binding protein
KO    Knock out
LCFA  Long chain fatty acid
LF    Low fat
LFABP Liver fatty acid binding protein
LFD   Low fat diet
LPS   Lipopolysaccharide
LRAT  Lecithin retinol acyltransferase
LRC   Label retaining cell
MCP1  Monocyte chemoattractant protein 1
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>MG</td>
<td>Monoacylglycerol</td>
</tr>
<tr>
<td>MGAT</td>
<td>Monoacylglycerol acyl transferase</td>
</tr>
<tr>
<td>MGL</td>
<td>Monoacylglycerol lipase</td>
</tr>
<tr>
<td>MHO</td>
<td>Metabolically healthy obese</td>
</tr>
<tr>
<td>MUC</td>
<td>Mucin</td>
</tr>
<tr>
<td>NAE</td>
<td>N-acylethanolamine</td>
</tr>
<tr>
<td>NAFLD</td>
<td>Non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>NHR</td>
<td>Nuclear hormone receptor</td>
</tr>
<tr>
<td>OEA</td>
<td>Oleoylethanolamide</td>
</tr>
<tr>
<td>PAM</td>
<td>Protopancer adjacent motif</td>
</tr>
<tr>
<td>PAS</td>
<td>Periodic acid-Schiff</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PCTV</td>
<td>Prechylomicron transport vesicles</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>pIF</td>
<td>Purified IFABP</td>
</tr>
<tr>
<td>PL</td>
<td>Phospholipids</td>
</tr>
<tr>
<td>pLF</td>
<td>Purified LFABP</td>
</tr>
<tr>
<td>PPAR</td>
<td>Peroxisome proliferator-activated receptor</td>
</tr>
<tr>
<td>PPRE</td>
<td>Peroxisome proliferator response element</td>
</tr>
<tr>
<td>PYY</td>
<td>Peptide tyrosine tyrosine</td>
</tr>
<tr>
<td>RAR</td>
<td>Retinoic acid receptor</td>
</tr>
<tr>
<td>RER</td>
<td>Respiratory exchange ratio</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>RXR</td>
<td>Retinoid X receptor</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>SCFA</td>
<td>Short chain fatty acid</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SFA</td>
<td>Saturated fatty acid</td>
</tr>
<tr>
<td>sgRNA</td>
<td>Guide RNA</td>
</tr>
<tr>
<td>SR-B2</td>
<td>Scavenger receptor CD36</td>
</tr>
<tr>
<td>SREBP</td>
<td>Sterol regulatory element binding protein</td>
</tr>
<tr>
<td>ssDNA</td>
<td>Single strand DNA</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>TBP</td>
<td>TATA-binding protein</td>
</tr>
<tr>
<td>TG</td>
<td>Triacylglycerol</td>
</tr>
<tr>
<td>TJ</td>
<td>Tight junction</td>
</tr>
<tr>
<td>UFA</td>
<td>Unsaturated fatty acid</td>
</tr>
<tr>
<td>UPR</td>
<td>Unfolded protein response</td>
</tr>
<tr>
<td>Vcre</td>
<td>Villin Cre</td>
</tr>
<tr>
<td>VLCFA</td>
<td>Very long chain fatty acid</td>
</tr>
<tr>
<td>VLDL</td>
<td>Very low density lipoprotein</td>
</tr>
<tr>
<td>VN</td>
<td>Vagus Nerve</td>
</tr>
<tr>
<td>WT</td>
<td>Wild-type</td>
</tr>
<tr>
<td>XBP1</td>
<td>X-box-binding protein1</td>
</tr>
<tr>
<td>Xbp1s</td>
<td>Spliced X-box-binding protein1</td>
</tr>
<tr>
<td>ZO1</td>
<td>Zonula occludens 1</td>
</tr>
</tbody>
</table>
Chapter 1

Introduction and Review of the Literature
Introduction

Lipids are a broad class of biomolecules that are soluble in non-polar solvents. This class of biomolecule includes, but is not limited to, fatty acids (FA), triglycerides (TG), cholesterol, fat-soluble vitamins, and phospholipids (PL). While they vary in numerous properties, such as hydrophobicity, they can all be extracted by organic solvents. Such diversity allows for lipids to participate in an array of physiological processes, with lipids playing roles in energy storage, cell signaling, and the modulation of cellular structures via alterations is cell membranes. In the context of human health, it is particularly important to point out that lipids are an important source of energy in the diet, since they have a higher caloric density (kcal per gram) when compared to carbohydrates and protein.

Obesity is a multifaceted disease that is characterized by excessive fat storage, and is often accompanied by metabolic dysfunction in multiple tissues. In 2005 it was estimated that obesity and obesity-derived illnesses cost the United States 190.2 billion dollars, representing 20.6% of all medical expenses. Data from the third National Health and Nutrition Examination Survey (NHANES III) has demonstrated that as of 2008 two thirds of US adults are considered overweight or obese. Obesity is now considered to be the leading cause of preventable death around the world. Dietary lipid quantity and quality have been found to be related to obesity and obesity-related comorbidities such as cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and several types of cancer. Dietary fat is important to human health, and its ingestion has downstream effects on metabolically active tissues, such as the liver and the gastrointestinal (GI) tract. Therefore, it is of integral importance to understand how dietary lipids are absorbed and processed by the human body, allowing for better informed attempts at nutritional and/or pharmacological interventions.

The overall aim of the research in this dissertation is to elucidate the function of the enterocyte fatty acid-binding proteins (FABPs), liver-FABP (LFABP or FABP1) and intestinal-FABP (IFABP),
in the small intestine. LFABP, which is also expressed in the liver, and IFABP, which is solely expressed in the small intestine, are members of the FABP family, a family of intracellular lipid binding proteins that have high affinities for FAs\textsuperscript{11,12}. While these two proteins only share about 29\% amino acid sequence homology, their tertiary structures are very similar and they are both highly expressed (Fig 1-1)\textsuperscript{11}. However, it is unusual for proteins with identical functions to be expressed within the same cell type; thus, it is generally believed that LFABP and IFABP play different roles relating to intestinal lipid metabolism. In these studies, transgenic mice that do not express LFABP or IFABP in the intestine were used to help elucidate their individual functions.
Figure 1-1: LFABP and IFABP structure. The ribbon diagrams of lowest-energy solutions structures for A, apo-LFABP \(^{13}\) and B, apo-IFABP \(^{14}\). Tertiary structural features of the FABP family include 2 antiparallel β-helix sheets with 5 strands that form the “clam shell” ligand binding pocket.
Previously, comparative studies using IFABP<sup>−/−</sup> and whole-body LFABP<sup>−/−</sup> mice revealed only modest differences when mice were fed a chow diet<sup>15</sup>. However, subsequent studies performed using mice challenged with 45% Kcal high fat (HF) diets revealed dramatic whole-body phenotypic differences, with IFABP<sup>−/−</sup> mice being resistant to diet induced obesity (DIO), while LFABP<sup>−/−</sup> mice became more obese, but remained relatively healthy<sup>16</sup>. The present work involved the same HF feeding protocol. For the IFABP<sup>−/−</sup> mice, phenotypic changes in the intestine that could alter whole-body phenotypes were assessed. Additionally, we developed a novel tissue-specific knock out strain of the LFABP<sup>−/−</sup> mice, allowing us to assess how the ablation of LFABP specifically in the small intestine may lead to alterations at the whole-body level in response to a HF challenge. The overall goal of this work is to uncover the individual effects of these two highly expressed small intestinal FABPs that are similar in structure, but appear to have different functions. More specifically, it is of importance to understand the mechanisms of intracellular lipid assimilation and trafficking in the small intestine so that appropriate nutritional and/or pharmaceutical interventions can be developed to eliminate or ameliorate lipid-related chronic diseases, such as obesity, type 2 diabetes mellitus, and CVD. In the following introductory sections, an overview of lipid consumption, digestion, and absorption will be presented, with emphasis placed on the morphological and cellular structures of the small intestine. This will be followed by a review of the current knowledge about the FABP family, and the previous studies that assessed mice null for either LFABP or IFABP.

**Dietary Triglycerides**

In the United States, dietary lipid represents 32-37% of caloric intake in adults<sup>17,18</sup>. The main challenge related to the digestion and absorption of dietary lipid is that without modulation, they would be insoluble in the aqueous environment that they would encounter within the intestinal lumen and within the absorptive enterocytes. In order for the absorption of lipid to be efficient, the body has a complex set of mechanisms that allow for dietary lipid to be processed, packaged,
and transported. These processes are initiated in the stomach but continue in the small intestine. The efficient digestion of dietary lipid depends on the combination of enzymes, transport proteins, and bile acids that allow the non-polar and aqueous components to mix more readily.

While many types of lipids are present in the diet, triglycerides (TG) are the major source of dietary lipid, representing greater than 90% of the lipid consumed. TGs consist of three FAs esterified to a glycerol backbone. In the human diet, that majority of TGs that are consumed are rich in long chain FAs (LCFA), which contain 14 or more carbons in the chain. Additionally, the FAs that make up the TG molecule are either saturated FAs (SFA) or unsaturated FAs (UFA). Animal products, such as lard or butter, tend to be rich in SFAs, while plant oils, such as olive oil and soybean oil, are rich in UFAs. The United States and other Western populations are known to consume diets that are rich in saturated LCFAs, such as palmitate (C16:0) and stearate (C18:0). Chronic consumption of high levels of long chain SFAs has been linked to higher risk of cardiovascular disease (CVD), an obesity-related comorbidity that has had increasing prevalence in Western societies. Conversely, diets rich in long chain UFAs, such as the Mediterranean diet, seem to be associated with a more healthy cardiovascular profile.

**Digestion of Triglycerides**

Most food components, including dietary lipid, are ingested in a form that is not readily available for use by the body. In order for the body to access these components, they need to be broken down into smaller components that can then be absorbed, assimilated, and moved into circulation. The gastrointestinal (GI) tract is responsible for carrying out the functions of ingestion, digestion, and absorption. Components of the GI tract include the oral cavity, pharynx, esophagus, small intestine, large intestine, and rectum. Additionally, accessory organs such as the liver, gallbladder, and pancreas provide secretions that are necessary for processing the nutrients within the GI tract. Digestion of dietary TG beings in the stomach, where the mechanical mixing of the stomach contents, in the form of grinding and peristaltic
movement, helps to emulsify the lipids in the food bolus, forming chyme \(^1,19\). Some of the TG is hydrolyzed to diacylglycerol (DG) and FA via gastric lipase, an enzyme that is secreted by chief cells of the gastric mucosa \(^26,27\). While gastric lipase has an optimal pH of around 4, the enzyme is still active at pH 6 to 6.5, allowing this lipase to process TG as the chyme moves from the stomach, through the pyloric sphincter, and into the duodenum \(^27\). Overall, the digestion of dietary fat in the stomach is relatively limited, but the processing that occurs is integral to its subsequent digestion in the lumen of the small intestine.
Figure 1-2: Components and histological organization of gastrointestinal tract-related organs. A, location of GI tract and accessory digestive organs. B, overall organization of the physiological layers of the organs for different regions of the GI tract. Adapted from Ash, Morton, and Scott. Reprinted with permission from McGraw-Hill Education © 2013.
As the acidic chyme moves into the duodenum, it triggers the release alkaline secretions from the Brunner glands and bicarbonate-rich secretions from the pancreas, resulting in the neutralization of the gastric acid that the chyme has been exposed to. The pancreas also secretes pancreatic lipase and colipase into the intestinal lumen, allowing pancreatic lipase to facilitate the hydrolysis of the remaining TG and DG in the chyme, forming 2-monoacylcerols (2-MG) and FAs. For efficient absorption of the lipophilic MGs and FAs in the lumen to occur, these digestion products must be solubilized. Micellar solubilization by bile salts allows these lipid digestion products to cross the barrier that is present in the form of the “unstirred water layer” that surrounds the epithelial surface. Bile salts are detergents that are synthesized in the liver and stored in the gallbladder. As the chyme initially moves into the duodenum, in addition to the pancreatic secretions and the secretions of the Brunner glands, bile, which contains bile salts, bilirubin, phospholipids, water, cholesterol, amino acids, and steroids is also secreted. This combination of secretions allows for the emulsification of dietary lipids via micelle formation. Once formed, these micellar lipid products are able to easily cross the unstirred water layer, resulting in significantly increased aqueous concentrations of FAs, MGs, and other lipid species.

**Small Intestine Composition and Structure**

In the GI tract, the small intestine is major site of dietary lipid absorption and assimilation. The small intestine of an adult human is about 500 to 700 cm in length, while the average mouse small intestine length is about 35 cm. Starting at the pyloric sphincter and ending at the ileocecal valve, the small intestine forms a long tube that can be divided anatomically intro three sections: the duodenum, jejunum, and the ileum. These regions vary in length, with the duodenum, jejunum, and ileum consisting of approximately 5, 38, and 57% of the total length, respectively. There are no clear morphological distinctions between connecting sections. However, certain characteristics, such as the prevalence of certain cell types or size of specific morphological
structures, are gradually altered depending on the intestinal region. Lipid absorption primarily occurs in the jejunum, while bile acid reuptake mainly occurs in the ileum.  

Like other regions of the GI tract, the small intestine contains several layers of cells. These layers include the mucosa, submucosa, muscularis, and serosa (Fig 1-2B). The mucosal layer contains cells that are integral for luminal nutrient absorption and modulation of immune function. The mucosa forms small finger-like folds, known as villi, which function to increase the surface area of the luminal nutrient contact for enhanced absorption. These villi are lined with a specialized type of epithelial cell called enterocytes, which are the most abundant cell type of the small intestine, and are primarily involved with the uptake and processing of dietary nutrients. These villi are covered in small hair-like projections on the apical (lumen-facing) surface of the enterocyte called microvilli. When magnified, these microvilli resemble the hairs of a paint brush, which has led to the apical surface of the enterocytes also being described as the “brush border membrane”. The combination of the mucosal folds, villi, and microvilli leads to a small intestinal structure with a surface area that is about 600 times greater than that of a similar length simple cylinder, which enhances nutrient absorption.  

In addition to enterocytes, the small intestinal mucosa contains several other types of cells (Fig 1-3A). An array of enteroendocrine cells are present throughout the GI tract, assisting with processes that involve nutrient sensing and alterations in intestinal motility (Fig 1-3B). Within the small intestine, some of the types of enteroendocrine cells that are present include I cells, S cells, M cells, and K cells; like many other intestinal epithelia cell types, the relative abundance of different cell types is influenced by the region of the small intestine. The small intestinal epithelium also contains a secretory cell type, called goblet cells, which secrete mucus that acts as an initial defensive barrier, providing protection from physical and chemical challenges. The mucus layer can be divided into two functional components: the top layer, or loosely adherent layer, which is able to trap bacteria and prevent them from interacting with the epithelium, and the
Figure 1-3: Cells of the gastrointestinal tract that are present in the small intestine. A, The intestinal crypt-villus axis. Stem cells in the crypt base give rise to transit amplifying cells. These cells differentiate into enterocytes, enteroendocrine cells, Paneth cells, and goblet cells. LRC, label retaining cells; CBC Cell, crypt base columnar cell. Graphic by Shaker and Rubin. Adapted by permission from Elsevier: Translational Research © 2010. B, the enteroendocrine cell types of the GI tract, and the peptide hormones that each cell has been traditionally associated with. 5-HT, 5-hydroxytryptamine; CCK, Cholecystokinin; GIP, Gastric inhibitory polypeptide; GLP-1,
bottom layer, or firmly adherent layer, which provides structural support and provides a critical barrier for preventing bacterial adhesion to the epithelium\textsuperscript{38,42,43}. The amount of goblet cells present in the small intestine increases from the duodenum to the ileum, and reaches maximal abundance in the distal colon\textsuperscript{37}.

The epithelial cells of the villi have a relatively rapid turnover period, with the average lifespan ranging from approximately 3 to 5 days\textsuperscript{26,44}. As they age, these cells travel towards the tip of the villi, and are eventually sloughed off into the lumen\textsuperscript{45}. In between villi, new epithelial cells are produced by stem cells located in the crypts\textsuperscript{44}. Paneth cells, another hypersecretory cell type of the small intestine, are also located in the crypts, where they secrete antimicrobial peptides and proteins that influence cell differentiation\textsuperscript{44}. Unlike the other cell types of the small intestine, Paneth cells appear to have a longer lifespan, lasting about 15 to 17 days\textsuperscript{44}.

The various cell types of the SI connect with one another by macromolecular protein structures that are called tight junctions (TJs)\textsuperscript{46,47}. Several transmembrane proteins, such as claudins, occludins, and junctional adhesion molecules (JAMs) form TJs that can either induce the formation of tightening gate-like structures, or loosening pore-like structures\textsuperscript{46,48–50}. The relative proportion and distribution of specific TJ proteins will influence whether a tighter or looser structure forms, which in turn will impact the overall permeability of the small intestine. A small intestine that has relatively high permeability can lead to the translocation of various bacterial products, such as lipopolysaccharide (LPS), which can then lead to chronic inflammation and tissue damage\textsuperscript{48,50}. However, it is important for the small intestine to be at least semi-permeable, as this permeability allows for the paracellular uptake of small nutrients and water\textsuperscript{51–53}. During the course of these studies it was observed that HF fed mice lacking IFABP appear to have an intestinal fragility phenotype, with the intestine breaking easily upon removal. It was hypothesized that the IFABP\textsuperscript{−/−} mice may have alterations in intestinal permeability that could predispose their small intestine towards being more fragile. Thus, one of the aims of this work focuses on
assessing aspects intestinal morphology and physiology that might influence the durability of small intestinal tissue.

The basolateral side of the enterocytes more directly interacts with the other layers of the small intestine. In the submucosal region, the lymphatic capillaries transport the chylomicrons that have been formed by the enterocytes (to be discussed below), allowing for these TG-rich lipoproteins to be delivered into circulation. The submucosal layer provides structural support, and access to the blood supply. Underneath the submucosal layer, the muscularis layer provides additional structural support, and plays an important role in the transit of nutrients. Peristaltic contractions along with signaling from enteroendocrine cells have great influence over the muscular contractions that push the digesta forward. The rate of the muscular contractions is important, since efficient uptake of dietary nutrients depends on how long the nutrients in the lumen are exposed to digestive enzymes. Below the muscularis layer is the serosal layer, which provides an additional layer of protection for the small intestine through secretions that lubricate its movement within the peritoneal cavity.

**Enterocyte FA and MG Uptake**

After the hydrolysis of a TG molecule in the intestinal lumen, two FAs and one 2-MG are present in the intestinal lumen. Unlike TG, these lipid species can be absorbed across the apical side of the intestinal enterocyte through transcellular processes. Yet, the exact mechanism of uptake of these lipids is not fully understood. It is known that the dietary lipid products can be taken up via passive diffusion, where the mixed micelles, containing the solubilized dietary lipid products, are thought to move dietary FAs and MGs through the un stirred water layer to the brush border membrane, for subsequent uptake. This process, which depends on the concentration of intracellular FA and 2-MG remaining low when compared to luminal FA and 2-MG, is facilitated by the rapid intracellular re-esterification of these lipids back into TG. Although passive diffusion of dietary lipid products is known to occur, kinetic studies have shown that the uptake of
FA is saturable, which supports the involvement of transport proteins. However, uptake of FA can still occur after proteolytic treatment of the brush border membrane, which also supports a role for passive diffusion as well.

Enterocyte processing of FA depends on the site of entry, with exogenous FAs entering from the apical side, while endogenous FA enters from the basolateral side. Though both sides of the enterocyte express membrane bound transport proteins that are thought to be involved in FA uptake, it is important to note that intestinal lumen free FA concentration is estimated to be in the low micromolar (μM) range, while estimated concentration in circulation is proposed to be in the low nanomolar (nM) range. This difference in luminal FA versus FA in circulation concentrations indicates that the relative contribution of FA transporters to total FA uptake in vivo is likely to be relatively small compared to their contribution to FA uptake in other tissues.

Instead, bulk uptake of apical FA likely occurs through passive diffusion, while FA transporters likely play a more important role in the uptake of basolateral FA and/or nutrient sensing.

There have been several proteins that have an affinity for binding FA that are thought to play a role in the carrier-mediated uptake of dietary FA. Initially fatty acid transport protein 4 (FATP4) was thought to play a role in apical FA uptake. However, it was observed that FATP4 is localized to the endoplasmic reticulum (ER), and functions to catalyze the conversion of FA into fatty acyl CoAs. Additionally, FATP4-null mice do not develop steatorrhea, and do not have reduced intestinal FA uptake, further suggesting that this protein does not play a large role in the efficient uptake of dietary FA.

Cluster of Differentiation 36 (CD36), also known as scavenger receptor CD36 (SR-B2) and FA translocase (FAT), is another enterocyte membrane protein that is thought to play a role in dietary FA uptake. Scavenger receptors are membrane proteins that are characterized by being able to recognize similar molecular patterns in their ligands, rather than a specific epitope. CD36 is highly expressed in throughout the small intestine, though its expression is highest in the most
proximal portion, where the bulk of dietary lipid uptake occurs. While its relative contribution to FA uptake in the small intestine is thought to be relatively low, CD36 mediated uptake of FA exerts a regulatory effect, inducing increased chylomicron production and increased secretions from enteroendocrine cells. Aside from very long chain FA (VLCFA), which have carbon chains that are greater than or equal to 22 carbons in length, CD36 mice do not appear to malabsorb dietary lipid. However, in response to high fat (HF) feeding, CD36 mice appear to have a shift in the region of lipid absorption, with more lipid being taken up in the more distal regions of the small intestine. Thus, intestinal CD36 does not appear to be necessary for bulk uptake of dietary lipid, but rather acts as a lipid sensor in the proximal portion of the small intestine, regulating the enteroendocrine cell responses to various types of lipid challenges while also modifying chylomicron production in enterocytes.

Other putative FA transport proteins are highly expressed in the small intestine, though relative to CD36, less work has been performed to examine their influence on luminal FA uptake. The scavenger receptor class B type 1 (SR-B1) is another member of the CD36 family this is abundantly expressed in the small intestine. Like CD36 mice, SR-B1 mice do not have reduced intestinal FA absorption. The small intestine also expresses the plasma membrane FA binding protein (FABPpm), and antibody inhibition of this protein has been shown to lead to reduced uptake of FA in vitro. While no additional work has examined its role in intestinal FA uptake, other studies using skeletal muscle have revealed that FABPpm plays an important role in response to physiological states in which skeletal muscle is actively taking up plasma FA, such as fasting or endurance exercise.

Similar to FAs, 2-MGs are also hypothesized to be taken up into the enterocyte through both passive diffusion and active transport mechanisms. Just like FAs, in vitro studies using Caco-2 cells revealed that uptake of MG is saturable. Interestingly, the addition of excess FA, but not
DG, to the medium of Caco-2 cells led to reduced uptake of 2-MG, suggesting that the same transport proteins may be involved in the uptake of both FA and 2-MG into the enterocyte.

**Intestinal Lipid Processing**

One of the main tasks of enterocytes is to process dietary lipids to be packaged and eventually exported to other tissues for use, meaning that enterocytes are periodically and consistently exposed to lipid challenges that many other cell types would not normally be exposed to. Additionally, inside of the enterocyte, like other cell types, the excessive buildup of FA can induced cytotoxicity. Thus, the cell must process the FAs in order to prevent their accumulation as well as to provide lipid substrates to other tissues. Dietary FAs and 2-MGs are mainly reconstituted back into TG. First, FAs must be activated by being converted into fatty acyl CoA. This reaction is catalyzed by acyl-CoA synthetase long chain family members 3 and 5 (ACSL3, ACSL5), or FATP4. The formation of fatty acyl-CoA from FA ensures that the concentration gradient favors the continued uptake of FA from the lumen into the enterocyte. After activation, fatty acyl-CoA is able to be incorporated into TGs. These TGs are primary packaged into large ApoB48-containing lipoprotein particles called chylomicrons, which are subsequently secreted from the basolateral side of the enterocyte into the lymph, and then eventually to the general circulation.

In enterocytes, TG synthesis can occur via 2 different pathways. The predominant pathway uses monoacylglycerol acyl transferase-2 (MGAT2), which is located in the ER, to catalyze the acylation of MGs into DGs. The resultant DG can be further acylated by diacylglycerol acyl transferase (DGAT) to reform TG. Unlike other tissues, due to the high abundance of MGs formed from dietary TG in the intestinal lumen, the MGAT pathway is the predominant route for TG formation in the intestinal enterocyte, accounting for approximately 75% of the TG that is synthesized.
Figure 1-4: Uptake and re-esterification of dietary FA and MG in the intestinal enterocyte.

In the lumen, TGs are hydrolyzed by lipases, forming FAs and 2-MGs. Re-esterification of FAs and MGs primary occurs via the MGAT pathway, though GPAT pathway is alternative route for TG synthesis. FA; Fatty acid; FA CoA, Fatty acid acyl coenzyme A; GPAT, glycerol-3-phosphate acyltransferase; AGPAT, 1-acylglycerol-3-phosphate acyltransferase.; PAPase, phosphatidic acid phosphatase, MGAT, Acyl-CoA:monoacylglycerol acyl transferase-2; DGAT, diacylglycerol acyltransferase; MAG, monoacylglycerol, BBM, brushborder membrane; BLM, basolateral membrane. Figure from Pan and Hussein. Adapted by permission from Elsevier: Biochimica et Biophysica Acta © 2012.
When there is low MG available, an alternative pathway for TG synthesis, known as the glycerol-3-phosphate acyl transferase (GPAT) pathway exists. This pathway involves the acylation of glycerol 3-phosphate to form phosphatidic acid, which is subsequently hydrolyzed to release inorganic phosphate and form DG. This DG can then be esterified by DGAT to form TG.

In the enterocyte, in addition to being used for TG synthesis and subsequent release into circulation in the form of chylomicrons, FAs and MGs can be utilized for other cellular functions. Some FAs and 2-MGs that are reincorporated into TGs can be stored in intracellular lipid droplets for future use. Fatty acyl-CoAs formed from FA can also be incorporated into membrane phospholipids, with the type of acyl chain that is incorporated having an influence on various membrane properties. FAs may also be used by the mitochondria or peroxisomes for oxidation, though this process does not represent a major component FA use in enterocytes. Additionally, FAs and MGs can play roles in the regulation of gene expression and cell signaling by serving as ligands for nuclear hormone receptors (NHRs) and G-protein coupled receptors (GPCRs).

**Lipid Sensing and Signaling in the Intestine**

In addition to being the major site of dietary lipid absorption, the small intestine also plays an important role in nutrient sensing. Throughout the small intestine enteroendocrine cells are present, secreting important peptide hormones in response to the presence or lack of specific nutrients, leading to the alteration of GI enzyme secretion, motility, and satiety. Enteroendocrine cells only comprise about one percent of the epithelial cells that line the gut, but when taken together, they form the largest endocrine organ system. In response to stimulation from luminal nutrients enteroendocrine cells secrete an array of peptide hormones, including glucagon-like peptide 1 and 2 (GLP-1, GLP2), cholecystokinin (CCK), peptide tyrosine tyrosine (PYY), and leptin. Historically it was hypothesized that specific differentiated enteroendocrine
cells were specialized, being mainly responsible for secreting individual peptide hormones for specific biological functions. For example, I cells were thought to only secrete CCK, a peptide hormone that is responsible for inducing gall bladder contraction and the secretion of pancreatic enzymes \(^99,100\). Likewise, K cells were thought to secrete GIP, stimulating insulin secretion, while M cells were shown to secrete motilin, a hormone responsible for inducing gastric movement \(^97,101\). Enterochromaffin cells secrete 5-hydroxytryptamine (5-HT), which in turn can modulate appetite and increase GI motility \(^36,97\). D cells and S cells secrete somatostatin and secretin, respectively, leading to reduced pancreatic secretion reduced secretion of gastric acid \(^36,97\). While the dogma has been that one type of enteroendocrine cell secretes a specific peptide hormone, more recent \textit{in vitro} and \textit{in vivo} studies have revealed that specific enteroendocrine cells are able to secrete an array of peptide hormone types, and that the relative abundance of hormones that are secreted, now referred to as the enteroendocrine “secretome”, is likely to be based on tissue location rather than specific cell lineage \(^99,102–104\). Indeed, ileal and colonic L cells have been shown to secrete GLP-1, GLP-2, and PYY, which in turn, can modulate food intake, GI motility, and insulin secretion \(^36,97,104,105\). Interestingly, mice that lack neurogenin 3 specifically in the intestine, which leads to elimination of all enteroendocrine cell subtypes, experience reduced lipid absorption and reduced weight gain, demonstrating that enteroendocrine cells are necessary for the efficient uptake of dietary lipid \(^106\).

The vagus nerve (VN) plays an integral role in the bidirectional communication that occurs between the central nervous system (CNS) and the GI tract. In the intestine, the afferent endings of the VN express receptors that bind the gut peptide hormones that are released from enteroendocrine cells of the GI tract \(^107\). For example, ghrelin stimulates increased food intake by inhibiting vagal afferent firing \(^107\). Exogenous administration of ghrelin to rodents acutely stimulates increased food intake, while rodents that have undergone a vagotomy do not respond to ghrelin administration \(^107\). Vagal tone can be altered by chronic nutritional challenges, with
components of the enteroendocrine cell secretome being modulated by alterations in food intake and body composition. Thus, altered vagal tone is commonly observed in chronic metabolic diseases such as obesity and type 2 diabetes mellitus.

In addition to the gut peptides secreted by the enteroendocrine cells, specific lipids can also act as signals to influence alterations in GI gene expression, appetite, and motility. This “message-modulator” function allows these lipids to amplify, diminish, or modify signals transmitted by other molecules. N-acylethanolamines (NAEs) are a group of lipids that can be synthesized by the intestine, and they have been shown to influence food intake in response to a dietary lipid challenge. Oleoylethanolamide (OEA) is a NAE that promotes satiety, and it can act as a potent agonist for the nuclear hormone receptor (NHR) peroxisome proliferator-activated receptor α (PPARα). Additionally, duodenal infusion of lipid, but not carbohydrates or protein, induces OEA mobilization, suggesting that OEA may be part of a negative feedback system that promotes reduced consumption of lipid.

Anandaminde (AEA) is an endocannabinoid (EC) that is also part of the NAE family of lipid signaling molecules. The EC system plays a critical role in energy homeostasis, including modulating food intake through a complex signaling system that is used by both the CNS and peripheral tissues. The EC system consists of the EC agonists, 2-arachidinoylglycerol (2-AG) and AEA, the cannabinoid receptors (CBRs), and the synthetic and degradative enzymes that are responsible for EC anabolism and catabolism, respectively. Increased levels of 2-AG and AEA can result in the overstimulation of the EC system via cannabinoid receptor 1 (CB1R) in both the CNS and peripheral tissues, promoting increased food intake. In the VN, CB1R activation induced slower GI transit, while chemical inhibition or genetic silencing results in more rapid intestinal transit. Chronic activation of the EC system in many organs and organ systems has been associated with obesity in both rodent models and humans. Additionally, intestinal levels of 2-AG have been shown to increase in response to dietary lipids,
but not carbohydrates. Taken together, these data support a vital role for intestinal lipids in the regulation of food intake and systemic energy balance in response to nutrient availability.

**Fatty Acid Binding Proteins**

Intracellular carrier proteins are thought to be required for the efficient trafficking of hydrophobic lipid species within the hydrophilic cytoplasmic milieu, although this has not been definitively shown. In the 1970s, members of the fatty acid-binding protein (FABP) family were initially identified as proteins within the cytosol that are able to bind FA. These 14-15 kDa proteins have highly conserved tertiary structures, consisting of 10 β-strands that form a ligand binding barrel, and 2 small α-helices. The FABP family consists of 9 FABPs and 4 cellular retinol-binding proteins (CRBPs). These FABPs are present in high abundance (~1-5% of total soluble protein) in the cytosol of most tissues, with some tissues expressing more than one type (Table 1-1). Interestingly the small intestine, a major site of lipid processing, expresses at least 4 members of the FABP family in high abundance, with the distribution of these proteins varying in different regions of the small intestine (Figure 1-5).
Table 1-1: The tissue location for the expression of FABP family members. Adapted from Storch and Corsico \textsuperscript{12}, and Napoli \textsuperscript{127}.

<table>
<thead>
<tr>
<th>FABP</th>
<th>Tissue Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver-FABP (FABP1)</td>
<td>Liver, small intestine (jejenum&gt;duodenum&gt;&gt;ileum), kidney</td>
</tr>
<tr>
<td>Intestine-FABP (FABP2)</td>
<td>Small intestine (jejenum&gt;ileum&gt;duodenum)</td>
</tr>
<tr>
<td>Heart-FABP (FABP3)</td>
<td>Cardiac muscle, skeletal muscle, brain, kidney, brown adipose tissue</td>
</tr>
<tr>
<td>Adipocyte-FABP (FABP4)</td>
<td>Adipocyte, macrophage, dendritic cell</td>
</tr>
<tr>
<td>Epidermal-FABP (FABP5)</td>
<td>Skin, esophagus, adipocyte, macrophage, dendritic cell, mammary gland, brain, kidney, lung, heart, skeletal muscle, testis, retina, lens, spleen</td>
</tr>
<tr>
<td>Ileal-FABP (FABP6)</td>
<td>Small intestine (ileum)</td>
</tr>
<tr>
<td>Brain-FABP (FABP7)</td>
<td>Brain, skin</td>
</tr>
<tr>
<td>Myelin-FABP (FABP8)</td>
<td>Peripheral nervous system</td>
</tr>
<tr>
<td>Testis-FABP (FABP9)</td>
<td>Testis, adipose tissue</td>
</tr>
<tr>
<td>Cellular Retinol Binding Protein 1</td>
<td>Most tissues</td>
</tr>
<tr>
<td>Cellular Retinol Binding Protein 2</td>
<td>Small intestine (duodenum, jejunum &gt; ileum)</td>
</tr>
</tbody>
</table>
Though many members of the FABP family were initially shown to bind FA with high affinity, some members of the family also bind other hydrophobic ligands. Recently, it has been demonstrated that several FABPs are able to bind AEA and 2-AG \(^{128,129}\). It has been hypothesized that these FABPs act to enhance uptake and subsequent hydrolysis of these lipid species by their degradative enzymes, fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MGL) \(^{129-134}\). Since it is known that AEA and 2-AG modulate food intake, it is possible that members of the FABP family may play an important role in the regulation and maintenance of energy balance.

**Enterocyte FABPs**

The intestinal enterocyte expresses at least two members of the FABP family simultaneously (Fig 1-5A): liver-FABP (LFABP or FABP1), which is also expressed in the liver, and intestinal-FABP (IFABP or FABP2), which is solely expressed within the intestine \(^{11,15,16}\). While these proteins only share about 29% amino acid sequence homology, their tertiary structures are very similar. However, it is unusual for proteins with identical functions to be expressed within the same cell type; thus, it is generally believed that LFABP and IFABP play different roles relating to intestinal lipid metabolism. In humans, IFABP is less abundant than LFABP \(^{135,136}\), while mice express similar levels of LFABP and IFABP within the SI mucosa \(^{135-137}\).

In addition to LFABP and IFABP, the proximal small intestinal enterocytes also express cellular retinol binding protein 2 (CRBP2), representing 0.4-1.0% of total soluble protein (Fig 1-5B) \(^{127}\). CRBP2 binds retinol with a high affinity, and is thought to act as a chaperone to bring it to lecithin retinol acyltransferase (LRAT) so that LRAT may catalyze the conversion of retinol into retinyl ester \(^{127,138}\). In the distal small intestine another FABP, the ileal bile acid binding protein (ILBP or FABP6), is also present (Fig 1-5A). This protein is also able to bind FA, but has a higher affinity for bile acids \(^{139}\), and a lower affinity for FA when compared to LFABP and IFABP \(^{140,141}\), suggesting that ILBP plays a larger role in bile acid metabolism than FA metabolism.
**Figure 1-5:** Small intestinal location of enterocyte FABPs. A, RNA blotting mouse small (I need to eliminate the word “small”) intestine that was divided into 7 sections. The mRNA distribution of LFABP, IFABP, and ileal protein (ILBP) is shown, with LFABP having higher expression in the duodenum and jejunum, IFABP being most highly expressed in the jejunum, and ILBP being most highly expressed in the ileum. DU, duodenum; PJ, proximal jejunum; DJ, distal jejunum; IL, ileum; CE, cecum; PC, proximal colon; DC, distal colon. Figure from Sacchettini et al. 142. Adapted by
permission from American Society for Biochemistry and Molecular Biology: Journal of Biological Chemistry © 1990.  B, Western blotting for CRBP2. Lane 1 is purified CRBP2. Lanes 2, 3 and 4 are extracts of jejunal mucosa, ileum mucosa, and colonic mucosa, respectively. Lane 5 is purified CRBP1. Figure from Crow and Ong 143. Adapted by permission from the Proceedings of the National Academy of Sciences of the United States of America © 1993.

**LFABP**

As mentioned above, LFABP is an intracellular protein that is abundantly expressed in the intestinal enterocyte. It is present throughout the small intestine, but it most abundant in the duodenum and jejunum, where the majority of dietary lipid is absorbed 11. Previous *in vitro* studies have demonstrated that LFABP is able to bind FA with a high affinity, with $K_d$ values in the nanomolar range 144,145. LFABP is an atypical member of the FABP family in that it is able to bind two FA ligands instead of one 146. LFABP is also a unique FABP in that it transfers ligands to phospholipid (PL) membranes via an aqueous diffusion mechanism rather than the typical collisional mechanism 147. Additionally, LFABP has been shown to be able to bind other types of lipid, including but not limited to monoacylglycerols (MG), prostaglandins, and lysophospholipids 146. The cytosolic distribution of LFABP seems to be influenced by fasting and feeding cycles. During the fed state, LFABP is distributed throughout the cytosol, while during the fasted state it localizes to the apical membrane 148. LFABP has been shown to play an important role in the budding of prechylomicron transport vesicles (PCTVs) from the ER 58,88,149–151. These PCTVs are processed in the Golgi to form mature chylomicrons, which subsequently leave the enterocyte to enter lymphatic and then general circulation 58. This process allows for dietary lipid to be delivered to the rest of the body, and demonstrates that LFABP plays a role in influencing dietary lipid availability for other tissues, in addition to the small intestine and liver where it is expressed.

Several studies have been performed to investigate the role of LFABP in the regulation of lipid metabolism-related genes. It has been hypothesized that LFABP is able to act as a lipid
chaperone, carrying ligands to the lipophilic binding pockets of NHRs. For example, the LFABP gene has been shown to contain a peroxisome proliferator response element (PPRE), allowing for increased LFABP gene expression to be induced upon PPARα activation. PPARα is a NHR that is highly expressed in the liver and small intestine, and is typically associated with the induction of genes involved with FA oxidation. In the liver it has been shown that LFABP is able to transfer FAs to the nucleus and co-localize with PPARα, that LFABP directly interacts with PPARα, and that expression of LFABP enhances the transcription of many PPARα target genes. It has also been recently demonstrated that LFABP is able to bind synthetic PPARα agonists, resulting in LFABP translocation to the nucleus. In addition to PPARα, LFABP has also been shown to interact with hepatocyte nuclear factor 4 α (HNF4α), a NHR that regulates a wide array of physiological processes such as lipid metabolism, cell differentiation, and cell-cell structural interactions. FA oxidation in the liver and intestine is reduced in the absence of LFABP, further supporting its role in the regulation of gene expression. The expression of LFABP appears to also be influenced by the intake of dietary lipid, with increased lipid intake being associated with increased expression of LFABP in both the small intestine and liver. Gender also appears to influence LFABP expression, with female rats having increased hepatocyte LFABP expression when compared to male rats. Interestingly, estradiol treatment of castrated male rats resulted in hepatic LFABP levels similar to that of intact female rats, while testosterone treatment of ovariectomized female rats resulted in hepatic LFABP levels similar to that of intact males, showing sex steroids play a role in the regulation of LFABP expression.

While there have been no reported cases of deletion of the LFABP gene in humans, a human polymorphism has been described. This polymorphism, which is a substitution of an alanine for a threonine at position 94 (T94A), is associated with increased plasma TG and free FA levels, and non-alcoholic fatty liver disease (NAFLD). Chang liver cells transected with the T94A
LFABP variant were shown to have reduced uptake of FA, increased accumulation of cholesterol, and no change in TG accumulation when compared to cells transfected with the wild-type (WT) variant. However, it is important to note that “Chang liver” cells are not liver cells, but are instead derived from human cervical cancer cells, meaning that these cells are likely to not have the same physiological responses that cultured primary hepatocytes would.

The T94A allele results in LFABP with altered conformational structure and function. Expression of the T94A LFABP variant in human hepatocytes impairs ligand-induced PPARα transcription of β-oxidative enzymes. Interestingly fenofibrate, an activator of PPARα, is less effective at lowering plasma TG in humans that have the T94A variation, when compared to subjects that express the WT variation of LFAP. It is thought that the impaired activation of PPARα in response to the presence of the T94A LFABP variant is due to the altered protein structure of the variant, leading to alteration in ligand/protein interactions.

**IFABP**

While LFABP is abundantly expressed in both the liver and the intestine, IFABP is only expressed in the intestine. IFABP is present throughout the small intestine, though it is most highly abundant in the jejunum. Like LFABP, IFABP is also found distributed throughout the cytosol in the fed state, but localizes to the apical membrane during the fasted state. Unlike LFABP, IFABP does not appear to be involved in chylomicron formation. Instead, IFABP is thought to play a role in the efficient uptake and trafficking of luminal FA to various enterocyte organelles. Both of the enterocyte FABPs are also hypothesized to serve as cytosolic reservoirs for FAs, helping to prevent lipotoxicity while eventually directing the FAs to be converted into TGs, converted into PLs, or oxidized.

Like other members of the FABP family, IFABP has a high affinity for both saturated and unsaturated LCFAs, though compared to LFABP it has a lower affinity for unsaturated FAs.
Unlike LFABP, *in vitro* studies have shown that IFABP transfers FAs to membranes via a collisional mechanism that is typical of most members of the FABP family. Intestinal expression of IFABP is influenced by PYY, with greater IFABP expression being observed in response to PYY release. In mice, the ablation of LFABP does not induced compensatory upregulation of IFABP at the levels of gene expression and protein abundance; there is no compensatory upregulation of LFABP in response to IFABP ablation as well. Unlike LFABP, the IFABP gene does not contain a PPRE, and is likely not regulated by PPARα. The lack of compensatory upregulation in gene knockout mice, and differences in its regulation in response to NHRs and signaling peptides, provides additional indirect evidence that LFABP and IFABP have different functions with this small intestine.

Like LFABP, deletion of the IFABP gene has not been reported in humans, though a polymorphism has been identified involving a threonine to alanine substitution at amino acid 54 (A54T). This amino acid substitution results in an increased affinity for FA relative to the alanine-containing proteins. Individuals with the A54T variant were found to have higher rates of insulin resistance, elevated plasma TG, and atherosclerosis. *In vitro* and *ex vivo* studies have demonstrated that the A54T variant is associated with increased TG synthesis and secretion, which is consistent with the hyperlipidemia that is observed in human subjects.

**LFABP and IFABP in Intestinal Lipid Metabolism**

It has been proposed that the LFABP and IFABP are both involved in directing lipids towards the synthesis of either PL or TG within the enterocyte. Dietary lipids, such as FA and MG are delivered via the apical side of the enterocyte, and are mainly incorporated into TG and later secreted from the basolateral side of the enterocyte in the form of TG-rich lipoproteins known as chylomicrons. Conversely, bloodstream derived FA are transported into the enterocyte through the basolateral surface, and are primarily used for either PL synthesis or oxidation. Several *in vitro* and *ex vivo* studies have suggested that the enterocyte FABPs are involved in efficient uptake of FA from
both the intestinal lumen and the bloodstream. In a series of experiments performed by Alpers and colleagues, an intestinal explant system was used to study the roles of IFABP and LFABP in response to either an apical or basolateral FA challenge. It was observed that, regardless of the site of FA entry, LFABP was able to bind more FA than IFABP. Interestingly, IFABP bound more apically administered FA than basolateral FA, suggesting that IFABP plays a bigger role in the transport of dietary-derived FA rather than FA from the bloodstream. Additionally, immunohistochemistry (IHC) was used to observe the subcellular localization of IFABP and LFABP in rat enterocytes. It was observed that in the fed state, both enterocyte FABPs were distributed throughout the cytosol. However, in the fasted state, IFABP and LFABP both localized to the apical surface of the enterocyte. These series of experiments contributed to the hypothesis that the enterocyte FABPs are necessary for efficient uptake, assimilation, and trafficking of dietary FA.

**LFABP−/− and IFABP−/− Mice**

To study the enterocyte FABPs in a more physiologically relevant *in vivo* system, whole-body knockout mouse models were generated. For LFABP, two independent laboratories generated LFABP−/− mice on the C57BL/6 background. The St. Louis LFABP−/− mice were generated using mice from the Jackson Laboratory (BL6J), while the Texas LFABP−/− mice, from which our LFABP−/− mice are derived, were generated using Taconic mice (BL6N), and backcrossed to C56BL/6J mice to generate another line of LFABP−/− on the BL6 background (BL6J/N 0.6/0.4). The St. Louis LFABP−/− mice gain less weight than WT mice upon high fat feeding, while the Texas mice and our mice become obese. It is worth mentioning, however, that that the St. Louis LFABP−/− and Texas LFABP−/− lines share many similarities, including defective hepatic FA uptake, oxidation, and VLDL secretion.

One line of IFABP−/− mice has been generated on the C56BL/6J background by Vassileva and colleagues. There appeared to be a sexually dimorphic phenotype in response to HF feeding,
where male IFABP\textsuperscript{−/−} mice fed 35% Kcal fat HF diet with 1.25% cholesterol for 19 weeks, or fed 41% Kcal fat diets containing beef tallow of safflower oil for 14 days, were found to have increased BW relative to male WT mice, while female IFABP\textsuperscript{−/−} mice on the 35% Kcal fat HF diet with 1.25% cholesterol did not have significantly different BW when compared to female WT mice\textsuperscript{191}. Our IFABP\textsuperscript{−/−} mice are a substrain derived from the original line, and have been maintained on the C56BL/6J background.

In recent years, our lab has conducted direct comparative studies using both LFABP\textsuperscript{−/−} and IFABP\textsuperscript{−/−} mice. The initial studies, performed by Lagakos et al made use of chow fed male mice for baseline phenotypic evaluations\textsuperscript{15}. Previously it had been hypothesized that since both proteins are highly expressed within the small intestine, it is possible that ablating one may cause compensatory upregulation of the remaining enterocyte FABP. However, as previously reported by others\textsuperscript{185,191}, it was observed that mucosal expression of IFABP or LFABP, was not upregulated in mice null for LFABP or IFABP, respectively\textsuperscript{15}, lending credence to the hypothesis that these two proteins serve distinct functions within the small intestine. Additionally, Lagakos and colleagues observed that the BW of chow-fed LFABP\textsuperscript{−/−} and IFABP\textsuperscript{−/−} mice did not differ from WT mice\textsuperscript{15}. While it was initially hypothesized that the enterocyte FABPs were necessary for efficient uptake of dietary lipid, an analysis of fecal lipid content revealed that the ablation of LFABP or IFABP did not result in increased fecal lipid percentage in chow fed mice\textsuperscript{15}. Some modest phenotypic changes were observed during and at the end of the chow feeding protocol: IFABP\textsuperscript{−/−} mice were found to lose more fat mass, and LFABP\textsuperscript{−/−} mice lost less fat-free mass than WT mice, in response to fasting. Additionally, intraduodenally administered $[^{14}\text{C}]$ FA revealed that IFABP\textsuperscript{−/−} mice recovered more of the radiolabel in the form of PL in the mucosa, relative to WT mice, suggestion that IFABP may play a role in directing dietary FA towards the synthesis of TG\textsuperscript{15}. While LFABP\textsuperscript{−/−} mice did not differ from WT mice in terms of $[^{14}\text{C}]$ FA partitioning, intraduodenal delivery of $[^{3}\text{H}]$ monoolien resulted in increased incorporation of the label in mucosal PL, MG, and
DG, while incorporation of label into mucosal TG was decreased\textsuperscript{15}. This suggests that LFABP plays a role in directing dietary MG away from PL synthesis and towards TG synthesis. Interestingly, the ablation of LFABP resulted in reduced oxidation of intraduodenally administered \textsuperscript{[\textsuperscript{14}C]}FA \textsuperscript{15}. As has been shown in the liver \textsuperscript{16}, it appears that that LFABP plays a role in trafficking FA towards oxidative pathways within the enterocyte.

While no dramatic whole-body phenotypic differences were noted in either IFABP\textsuperscript{-/-} mice or LFABP\textsuperscript{-/-} mice fed a low fat (LF) chow diet \textsuperscript{15}, it was hypothesized that the lipid load of the chow diet was not high enough to sufficiently stress the mice lacking only one enterocyte FABP, especially since the single knockout mice still express high levels of the remaining enterocyte FABP. Thus, HF feeding studies were commenced and the findings of Gajda et al were quite dramatic: HF fed LFABP\textsuperscript{-/-} mice gained more weight and fat mass, relative to WT mice, while IFABP\textsuperscript{-/-} remained lean, gaining less weight and fat mass \textsuperscript{16}. It was also found that LFABP\textsuperscript{-/-} mice had lower respiratory exchange ratios (RERs) than WT mice, indicating that these mice primarily utilize lipid as an energy source \textsuperscript{16}. Conversely, the leaner HF fed IFABP\textsuperscript{-/-} mice were found to have higher RERs than WT mice, suggesting that these mice preferentially oxidize carbohydrate as an energy source \textsuperscript{16}. LFABP\textsuperscript{-/-} mice were found to have increased food intake, and IFABP\textsuperscript{-/-} mice were observed to have decreased food intake, relative to WT mice \textsuperscript{16}. However, an assessment of feeding efficiency revealed that the leanness of the IFABP\textsuperscript{-/-} mice and the increased BW and fat mass of the LFABP\textsuperscript{-/-} could not be fully explained by alterations in food intake \textsuperscript{16}. Most interestingly, an assessment of fecal lipid content revealed that even when challenged with chronic HF feeding, the amount of lipid in the feces did not differ between the three groups of mice \textsuperscript{16}, suggesting that the ablation of LFABP or IFABP does not result in malabsorption of dietary lipid. Thus, the prevailing idea that the enterocyte FABPs are critical for bulk dietary lipid assimilation requires further examination.
Summary

The intestinal enterocytes are thought to be integral to the absorption and assimilation of dietary lipid from the intestinal lumen. With dietary TG accounting for >90% of the lipid in the human diet, its hydrolysis products, MGs and FAs, are of particular importance in terms of what lipids the enterocytes are exposed to. LFABP and IFABP are both highly abundant lipid binding proteins that have high affinities for FAs, and they are hypothesized to be necessary for the efficient uptake and trafficking of lipids within intestinal enterocytes. While these proteins are from the same family and have similar structures, differences in ligand binding, specificities, affinities, and mechanisms of delivery have been observed, suggesting that these proteins play different roles within the small intestine in regards to the modulation of lipid transport and metabolism. Furthermore, in vivo studies in mice have shown that LFABP−/− and IFABP−/− mice respond drastically differently to chronic high fat feeding, with LFABP−/− mice becoming more obese, while IFABP−/− mice remain lean. This profound phenotypic divergence has provided further evidence that these have difference function within the small intestine. It is important to keep in mind that LFABP is also expressed in the liver, meaning that the phenotypes observed in the HF fed LFABP−/− can be a result of the response to lacking liver-LFABP, lacking small intestinal-LFABP, or some combination of the two. In regards to the IFABP−/− mice, it is important to note that while these mice remain lean on a HF diet, it was observed that the lean phenotype could not be fully explained by reductions in food intake. Since IFABP is only expressed in the small intestine, it is imperative to assess other aspects of intestinal physiology that might induce alterations in body weight and body composition. Therefore, the aims of this thesis project are:
Specific Aims

SPECIFIC AIM 1: To assess what the contribution of intestinal LFABP is to the obese phenotype that has been observed in HF-fed LFABP−/− mice.

As mentioned above, feeding LFABP−/− mice a HF diet resulted in increased BW, fat mass, and food intake relative to WT mice. Surprisingly, although LFABP−/− mice became obese they remained relatively healthy, being normoglycemic, normoinsulinemic, and also displaying reduced hepatic steatosis, and intestinal TG secretion rates similar to that of lean mice. Further, despite their obesity, the LFABP−/− mice were found to be more active, and our recent studies show that LFABP−/− mice have greater exercise endurance than WT mice. It has been recognized that a subset of the obese population is still found to be healthy, not displaying various comorbidities that are commonplace amongst obese people; this phenomenon has become known as the “metabolically healthy but obese” (MHO) state. The LFABP−/− mice thus appear to be a model of MHO. In order to understand the underlying causes of the LFABP−/− phenotype, it is critical to know whether it is dependent on the ablation of LFABP in the intestine or in the liver, or if simultaneous ablation is necessary. Thus, one of our aims focuses on generating LFABP conditional knockout (cKO) mice so as to assess the role of LFABP specifically within the small intestine that may influence the whole-body phenotypic changes in the LFABP−/− mice. To this end, body weight gain, body composition, food intake, indirect calorimetry, and other metabolic indicators will be used to assess whole-body energy homeostasis in the LFABP-cKO mice.

SPECIFIC AIM 2: To assess what changes are occurring within the small intestine of LFABP−/− mice that may explain the resistance to diet-induced obesity and the fragility of the small intestine.

As the enterocyte FABPs have long been thought to be involved in dietary lipid uptake and assimilation, it is tempting to speculate that HF fed IFABP−/− might malabsorb lipid in addition to
having a decreased food intake, explaining the observed lean phenotype. As noted above, however, the fecal lipid content did not vary between IFABP<sup>−/−</sup> and WT mice when challenged with either LF chow or 45% Kcal fat HF diets, suggesting that the IFABP<sup>−/−</sup> mice were not malabsorbing lipid<sup>15,16</sup>. It is possible that the lipid content of the 45% Kcal HFD is not sufficient to stress the absorptive capacity of the SI enterocytes, thus, as part of the second aim, we will examine the fecal fat content of mice fed a supraphysiological 60% Kcal fat diet. In addition, we will determine not only fecal lipid content, but also total fecal excretion, and the intestinal transit time of mice fed the 45% Kcal HF diet.

During organ collection, it was observed that the intestinal tissue of the HF fed IFABP<sup>−/−</sup> mice seemed to be more fragile than that of WT mice, with the tendency to easily break upon removal. We, therefore, also hypothesized that the ablation of IFABP may lead to alterations in intestinal structure and, perhaps, inflammation. Thus, part of the second aim will focus on gene expression, histological, and immunohistochemical analyses to assess SI integrity, morphology, and inflammatory status.
Chapter 2

The Generation and Whole-Body Phenotyping of Intestine-Specific Liver Fatty Acid-Binding Protein Knockout Mice
Abstract

Liver fatty acid-binding protein (LFABP or FABP1) is a highly abundant intracellular lipid binding protein that is expressed in liver and small intestine of mice. High fat (HF) feeding of male whole-body LFABP\textsuperscript{+/−} mice resulted in animals that appeared to be obese, yet metabolically healthy. LFABP\textsuperscript{+/−} mice gained more weight and had higher fat mass, but displayed better exercise capacity when compared to their wild-type (WT) controls. Intestine-specific ablation of LFABP (LFBAP\textsuperscript{int−/−}) resulted in male mice that did not differ from WT-LFABP floxed (LFABP\textsuperscript{fl/fl}) controls in body weight or body composition. On the other hand, female LFABP\textsuperscript{int−/−} mice were more obese than their LFABP\textsuperscript{fl/fl} counterparts. Both male and female LFABP\textsuperscript{int−/−} mice were found to have better exercise capacity. It appears that the ablation of both liver- and intestinal-LFABP, or perhaps ablation in liver only, may be necessary to induce the metabolically healthy obese (MHO) phenotype observed in whole body male LFABP knockout mice, but that intestine-specific ablation is sufficient to induce the improvement in exercise capacity.
**Introduction**

Obesity, a disease state that is characterized by excessive fat storage and is often accompanied by an array of metabolic comorbidities, is considered to be the leading cause of preventable death around the world. In addition the physical burdens placed on individuals, obesity and obesity-related illnesses represent a substantial financial burden economically. Prevalence has increased over the years, with two thirds of US adults are considered overweight or obese. With increased fat storage being integral to the development of obese phenotypes, dietary lipid quantity and quality are thought to play important roles in the etiology of obesity and its related comorbidities.

The absorptive enterocytes of the small intestine are primary responsible for the absorption and subsequent processing of dietary lipid. The abundance of triacylglycerol (TG), the primary component of dietary lipid, is elevated in Western diets. Absorption of dietary TG, after its luminal hydrolysis to fatty acid (FA) and monoacylglycerol (MG), is highly efficient, with greater than 95% of dietary lipid taken up. Once absorbed, it is thought that these hydrophobic lipid species require intracellular lipid binding proteins to be efficiently transported within the hydrophilic cytoplasmic milieu.

The intestinal enterocyte expresses at least two members of the FABP family simultaneously: liver-FABP (LFABP or FABP1), which is also expressed in the liver, and intestinal-FABP (IFABP or FABP2), which is solely expressed within the intestine. Two independent laboratories have generated LFABP−/− mice on the C57BL/6 background. The St. Louis LFABP−/− mice were generated using mice from the Jackson Laboratory (BL6J), while the Texas LFABP−/− mice, from which our LFABP−/− mice are derived, were generated using Taconic mice (BL6N), and backcrossed to C56BL/6J mice to generate another line of LFABP−/− on the BL6 background (BL6J/N 0.6/0.4). The St. Louis LFABP−/− mice gain less weight than WT mice upon high fat feeding, while the Texas mice and our mice become obese. It is worth
mentioning, however, that that the St. Louis LFABP\textsuperscript{−/−} and Texas LFABP\textsuperscript{−/−} lines share many similarities, including defective hepatic FA uptake, oxidation, and very low density lipoprotein (VLDL) secretion\textsuperscript{161,185,187,190}.

In our hands, feeding LFABP\textsuperscript{−/−} mice a HF diet results in increased body weight, fat mass and food intake relative to WT mice\textsuperscript{16}. Although LFABP\textsuperscript{−/−} mice become obese they appear to be relatively healthy, being normoglycemic, normoinsulinemic, and also displaying reduced hepatic steatosis, and intestinal triglyceride (TG) secretion rates similar to that of lean mice\textsuperscript{16,113,187,192}. Further, despite their obesity, the LFABP\textsuperscript{−/−} mice are more active\textsuperscript{16}, and additional studies show that LFABP\textsuperscript{−/−} mice have greater exercise endurance than WT mice. It has been recognized that a subset of the obese population is still found to be healthy, not displaying various comorbidities that are commonplace amongst obese people; this phenomenon has become known as the “metabolically healthy but obese” (MHO) state\textsuperscript{195,196}. The LFABP\textsuperscript{−/−} mice thus appear to be a model of MHO. In order to understand the underlying causes of the LFABP\textsuperscript{−/−} phenotype, it is critical to know whether it is dependent on the ablation of LFABP in the intestine or in the liver, or if simultaneous ablation is necessary. In this study, LFABP conditional knockout (cKO) were generated to assess the role of LFABP specifically within the small intestine, and to determine how much the intestinal LFABP contributes to the phenotype of the whole body LFABP null.

To generate the LFABP-cKO mice, the type II bacterial clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system was used as an efficient gene-targeting technology (Fig 2-1A)\textsuperscript{197,198}. Traditionally, mice that have a gene flanked by loxP sites (“floxing” of a gene) were generated by targeting in embryonic stem cells and subsequently producing germline chimeric mice\textsuperscript{199,200}. However, this process is time consuming, and inducing precise modifications can be unreliable. More recently, genome editing using direct microinjection of synthetic RNA-guided nucleases into zygotes has accelerated the production of gene-modified animals with precise alterations. The CRISPR/Cas system makes use of guide RNAs (sgRNAs)
that contain a targeting sequence (crRNA), and a Cas9 nuclease-recruiting sequence (tracrRNA) \(^{201}\). The Cas9 nuclease, when recruited, induces double-strand breaks (DSBs) at the sites of recognition. In order for specific alterations to DNA to be induced, single stranded (ss) DNA donors must be introduced so that they can be incorporated into the host organisms’ DNA via homology driven repair (HDR). To generate a cKO mouse using the CRISPR/Cas system, two separate sgRNAs must be used to introduced loxP sites upstream and downstream of a critical exon for a gene of interest. The resultant “floxed” mice can then be bred with mice that express Cre recombinase, driven by a reporter of interest (**Fig 2-1B**) \(^{202,203}\). The simultaneous expression the floxed gene with Cre recombinase will induce specific excision of the DNA located between the two loxP sites.
**Figure 2-1:** The generation of tissue specific knockout mice using the CRISPR/Cas and Cre/lox approach. 

*A*, gRNA allows for the specific targeting of a DNA sequence of interest. The Cas9 protein recognizes the DNA, and is able to induce a double strand DNA break. In the presence of single strand DNA donors, new DNA can be incorporated into the target sequence via homology driven DNA repair mechanisms, allowing for precise editing to occur. Figure from Singh et al.\textsuperscript{204} Adapted by permission from Genetics © 2015. 

*B*, Mating of the floxed mice with mice that are Cre mutants will generate double-transgenic mice, resulting in the tissue-specific ablation of the floxed gene in tissues that express the Cre recombinase transgene. Figure from Sauer\textsuperscript{202}. Adapted by permission from Elsevier: Methods © 1998.
Experimental Procedures

Generation of Intestine-specific LFABP null Mice

Conditional knockout mice were generated at The Rutgers Genome Editing Core Facility. The type II bacterial CRISPR/Cas system was used as gene-targeting technology to generate mice with loxP sites flanking critical exons of the *fabp1* gene (Fig 2-2A). Initially, two separate guide RNAs (gRNAs) were developed, each formed to contain a targeting sequence (crRNA), and a Cas9 nuclease-recruiting sequence (tracrRNA). The crRNA was a 20-nucleotide sequence that was homologous to sequences either upstream or downstream of exons 2 and 3 of the *fabp1* gene and located near a protospacer adjacent motif (PAM) sequence, allowing for the Cas9 nuclease activity to be directed to the *fabp1* alleles. Cas9 nuclease was used to induce double-strand breaks (DSBs) at the sites of recognition. In addition to the gRNAs and Cas9, single stranded (ss) DNA donors were used to introduce both loxP sites via homology driven repair (HDR) (Fig 2-2B). Like the WT *fabp1* gene, the ssDNA sequence also contains the crRNA targeting sequence. However, when the addition of the loxP site is successful, this causes the crRNA sequence to be separated from the PAM sequence that is required Cas9 recognition, preventing further DSBs from occurring. The ssDNA donor for the upstream loxP site also contained a PsiI restriction site, while the ssDNA donor for the upstream loxP site contained an EcoRI restriction site.

C57BL6/N mouse oocytes were microinjected with Cas9 protein, the ssDNA donors containing loxP, and the gRNA targeting downstream of the *fabp1* gene. Once fertilized with sperm from C57BL6/J mice, the resultant mice contained alleles having only one loxP site. The microinjection process was repeated for the oocytes from these mice, but the gRNA targeting the upstream site of the *fabp1* gene was substituted to ensure that critical exons of the *fabp1* gene would be flanked by loxP sites (LFABP\(^{fl/fl}\)).
Figure 2-2: **Strategy used to generate LFABP-cKO mice.** *A,* The sequence map for the altered Fabp1 gene. Distinct gRNAs were used to target locations upstream and downstream of critical exons 1 and 3 for the *fabp1* gene. Double strand DNA breaks were induced via recognition by and recruitment of Cas9 nuclease. In the presence of ssDNA donors, homology driven DNA repair results in the incorporation of new DNA into the *fabp1* gene. *B,* Sequences for the upstream and downstream ssDNA donors. Each donor contains loxP sequences and distinct crRNA targeting sequences. Upon the successful incorporation of the loxP site, the Cas9 nuclease is no longer able to target the crRNA, preventing further DSBs from occurring. The upstream ssDNA donor contains a Psil restriction site, while the downstream ssDNA donor contains an EcoRI restriction site, enabling for the resultant mice to be assessed for the presence of both the upstream and downstream loxP sites.
Animals

LFABP<sup>fl/fl</sup> mice on the mixed C57BL6/J and C57BL6/N background were backcrossed with WT C57BL6/J mice 4 additional times, yielding congenic LFABP<sup>fl/fl</sup> mice on the C57BL6/J background. The resultant LFABP<sup>fl/fl</sup> mice were then bred with mice that are hemizygous for Cre driven by the villin promoter (Vcre/+) to generate double-mutants (LFABP<sup>fl/+;Vcre/+</sup>), which were then be crossed to generate intestine-specific LFABP knockout (LFABP<sup>fl/+;Vcre/+</sup> or LFABP<sup>int/-</sup>) mice. This breeding scheme also allows for the continued propagation of LFABP<sup>fl/fl</sup>, which are used as littermate WT controls for their LFABP<sup>int/-</sup> counterparts. Mice were maintained on a 12-hour light/dark cycle, and allowed ad libitum access to standard rodent chow (Purina Laboratory Rodent Diet 5015) until the start of the study at 2 months of age.

DNA Extraction for Genotyping

DNA extraction was performed as described previously. In brief, a 0.5cm tail biopsy was incubated overnight at 37°C in lysis buffer (0.3M sodium acetate, 10mM Tris-HCL pH7.9, 1mM EDTA, 1% SDS, 0.2mg/mL proteinase K). The following morning, the lysate was cooled on ice, and the precipitate was pelleted. The supernatant was then placed into a new cool microcentrifuge tube, with subsequent ethanol precipitation being used to isolate the DNA.

For the genotyping of the LFABP<sup>fl/fl</sup> mice, forward and reverse primers were developed that allow for the assessment of the upstream lox P site, while a separate set of forward and reverse primers assessed the downstream loxP site in two separate PCR reactions. The primer sequences for the LFABP<sup>fl/fl</sup> protocols are as follows:

**Primers used for the upstream loxP**

FABP1A- AGACAAGTCAAAGATCATGAATGTGAG  
FABP1B- TGGCTCTTAGAGTGGAACACTTC
**Primers used for the downstream loxP**

FABP1C- CCGAGTTGATAGATCAGATC
FABP1D- GAAACAGGGCAAGGCCAGCTATG

After performing the reactions, the PCR products for the upstream loxP reaction were digested with PsiI, while the PCR products for the downstream loxP site were digested with EcoRI. Subsequently, gel electrophoresis on a 2% agarose gel was performed. WT mice that do not have the inserted loxP sites will only have one band for both the upstream (350BP) and downstream (540BP) reactions. However, LFABP\textsuperscript{fl/fl} mice will have two smaller bands for both the upstream (231BP and 119BP) and downstream (325BP and 215BP) reactions.

The genotyping protocol for the Vcre/+ mice used 3 primers for two separate PCR reactions. One primer, Vcre common, was used for both reactions. The Vcre-WT primer was used to detect a band that can be found in WT mice (~186BP), while the Vcre-mutant primer was used to detect a band that should only be observed in Vcre/+ mice (~150BP). Since the Vcre/+ mice must be maintained as hemizygotes\textsuperscript{205}, they should have bands for both the Vcre-WT reaction and the Vcre-mutant reaction. The primer sequences for the Vcre genotyping protocols are as follows:

**Vcre-WT reaction**

Vcre-Common- GCCTTCTCCTCTAGGCTCGT
Vcre-WT- TATAGGGCAGAGCTGAGGA
**Vcre-Mutant reaction**

Vcre-Common- GCCTTCTCCTCTAGGCTCGT  
Vcre-Mutant- AGGCAAATTTTGGTGTACGG

**High Fat Feeding, Body Weight, and Body Composition**

At 8 weeks of age, male and female mice were fed a 45% Kcal fat semipurified HF diet (D10080402, Research Diets, New Brunswick, NJ). The mice were maintained on this diet for 12 weeks, with BW measurements recorded weekly. Fat mass measurements were taken by MRI (Echo Medical Systems, LLC., Houston, TX) 2-3 days prior to starting the feeding protocol, and 2-3 days prior to sacrifice. The instrument was calibrated each time according to the manufacturer's instructions. At each time point, two measurements were recorded for each mouse and averaged.

**Indirect Calorimetry, Activity, and Food Intake**

Energy expenditure was assessed using the Oxymax system (Columbus Instruments, Columbus, OH) during week 11 of HF feeding. Mice were placed in an indirect calorimetry chamber (1 mouse per chamber) with food for 96 hours. The first 48 hours were used as an acclimation period, while the second 48-hour period was used to record activity, food intake, and energy metabolism measurements. VO2 and VCO2 (VCO2/VO2) were used to determine the Respiratory Exchange Ratio (RER). Energy expenditure was measured by the using the gas exchange measurements as follows: $(3.815 + 1.232 \times \text{RER}) \times \text{VO}_2^{206}$.

**Oral Glucose Tolerance Tests**

During week 11 of the HF feeding protocol, mice were be fasted for 6 hours prior to OGTT experiments. Blood was obtained via the tail vein, and glucose was measured using an Accu-
Check monitor (Roche). An oral gavage of 2g glucose/Kg body weight was administered, and blood was sampled at time points of 30, 60, 90, and 120 minutes post gavage.

*Treadmill Exercise Protocol*

Exercise testing used a treadmill incline at 25°. Mice were acclimated one day prior to the test by walking at 5 m/min. The test speed began at 6 m/min; after the first 5 minutes, the speed was increased by 3 m/min every 2 minutes. The treadmill makes use of a shock grid at the base (only contacted when the mice fail to keep up with the treadmill belt), which was kept at a low intensity. Fatigue was indicated when mice remained on the shock grid for 5 seconds, at which time the mice were removed from the apparatus, and the time to fatigue and total distance traveled were recorded.

*Blood and Tissue Preparation*

At the end of the experiment mice were fasted for 16 hours prior to sacrifice. At sacrifice whole blood was drawn; plasma was isolated after room temperature centrifugation for 6 minutes at 4000 rpm, and stored at -80°C. The livers were removed, weighed, immediately placed on dry ice, and stored at -80°C for further analysis. The small intestine from the pyloric sphincter to the ileocecal valve was removed, measured lengthwise, rinsed with 60mL of ice-cold 0.1M NaCl, and opened longitudinally. Intestinal mucosa was scraped with a glass microscope slide into tared tubes on dry ice.

*Blood Analysis*

ELISA kits were used to measure plasma insulin (EZRMI-13K, MilliporeSigma) and plasma leptin (EZML-82K, MilliporSigma). Samples were prepared and the analysis occurred following the manufacturer’s instructions. For plasma leptin, a leptin index was calculated that normalized values to fat mass for each animal. This was determined by taking the plasma leptin values for each mouse, and dividing it by their respective fat mass values.
Western Blotting

Small intestinal mucosa was harvested as described above, and homogenized in 10x volume of PBS pH 7.4 with 0.5% (vol/vol) protease inhibitors (Sigma8340) on ice with a Potter Elvejem homogenizer for 20 strokes. Total cytosolic fractions were obtained by ultracentrifugation (100,000g, 1 hour at 4°C) and protein concentrations were determined by Bradford assay. Thirty micrograms of protein were loaded onto 15% polyacrylamide gels and separated by SDS-PAGE. The proteins were then transferred onto 0.45μm nitrocellulose membranes using a wet transfer system (Bio-Rad) for 1 hour at 100 V. After transfer, total protein was visualized using Ponceau staining. Membranes were then blocked by incubating in 5% nonfat dry milk overnight at 4°C, and were subsequently incubated with an α-LFABP primary antibody (1:2000 for 1 hour at room temperature). After thorough washing, blots were then incubated in α-rabbit IgG-horseradish peroxidase conjugate (1:10,000) for 1 hour, and developed by chemiluminescence (WesternBright Quantum, Advansta, Menlo Park, CA). Protein expression was quantified by densitometric analysis with LI-COR Image Studio (Lite version 5.2). Target protein content was normalized to total protein content within a sample.

Statistical Analysis

All group data are shown as average ± SEM. Statistical comparisons were determined between genotypes on the same diet using a two-sided Student’s t-test. Differences are considered significant for P<0.05.

Results

The ablation of LFABP was specific to the small intestine

LFABP^{fl/fl} mice were crossed with Vcre hemizygotes to generate mice that are double mutants, with one allele that has the floxed LFABP gene, and one allele that contains villin-Cre (LFABP^{fl/+};Vcre/+). Subsequently, double mutant mice were crossed with LFABP^{fl/fl} mice to obtain
the intestine-specific LFABP−/− mice (LFABPfl/fl;Vcre/+ to be called LFABPint−/−), and littermate LFABPfl/fl mice that were used as controls (Fig 2-3AB). Ablation of LFABP in the intestine, but not the liver, of LFABPint−/− mice was confirmed by Western blotting (Fig 2-3C). Control LFABPfl/fl mice, which should be phenotypically similar to WT mice, express LFABP in both their liver and intestine (Fig 2-3C).
Figure 2-3: **Confirmation of generation of LFABP^{fl/fl} and LFABP^{int−/−} mice.** A, DNA gel showing PCR reactions for Vcre genotyping; B, DNA gel showing PCR reactions for lox P sites flanking the fabp1 gene. For the upstream loxP site the band at 350BP is indicative of an uncut WT band, while the 231BP and 119BP fragments are indicative an allele that contain the loxP site. For the downstream loxP site, 540BP indicated a WT allele, while 325BP and 215BP indicate an allele with the loxP site; C, Western blotting confirming the intestine-specific ablation of LFABP in LFABP^{int−/−} mice. Purified LFABP protein (pLF) was used as a positive control.
Male LFABP\textsuperscript{int/-} mice do not have altered body weight or body composition; female LFABP\textsuperscript{int/-} mice have higher body weight and increased fat mass

At 8 weeks of age, male and female LFABP\textsuperscript{fl/fl} and LFABP\textsuperscript{int/-} mice were challenged with a 45% Kcal fat HF diet. After 12 weeks on the diet, no differences were observed between male LFABP\textsuperscript{fl/fl} and LFABP\textsuperscript{int/-} mice in weekly BW (Fig 2-4A) or BW gain (Fig 2-4B). Additionally, the intestine-specific ablation of LFABP did not result in any alterations in body composition, with no changes in fat mass observed (Fig 2-4C). For females however, it was observed that the BW of LFABP\textsuperscript{int/-} mice was significantly greater than that of their LFABP\textsuperscript{fl/fl} counterparts starting at week 6 of their HF challenge (Fig 2-4D). Overall, female LFABP\textsuperscript{int/-} mice also had higher BW gain (Fig 2-4E) and greater fat mass than female LFABP\textsuperscript{fl/fl} mice (Fig 2-4F).
Figure 2.4: Body weight, body weight gain, and fat mass for LFABP<sup>fl/fl</sup> (●) and LFABP<sup>int-/int</sup> (■) mice after 12 weeks of 45% Kcal HF feeding. A, Male mice body weights (n=10); B, Male mice body weight gain (n=10); C, Male mice fat mass percentage (n=10); D, Female mice body weights (n=8-10); E, Female mice body weight gain (n=8-10); F, Female mice fat mass percentage (n=10).
The intestine-specific ablation of LFABP does not result in altered energy homeostasis

Mice were placed into the Oxymax system to assess food intake, respiratory exchange ratio (RER), and energy expenditure. For male LFABP^{fl/fl} and LFABP^{int-/-} mice there was no difference observed in the amount of food that was consumed (Fig 2-5 A and B). The intestine-specific ablation of LFABP in male mice did not result in differences in the average 24-hour RER as well (Fig 2-5C). Additionally, no differences in energy expenditure were observed (Fig 2-5D). Despite the observed differences in BW and body composition for the female LFABP^{fl/fl} and LFABP^{int-/-} mice, other energy homeostasis-related phenotypes were not altered, with no differences being observed in food intake (Fig 2-5E and F), 24-hour RER (Fig 2-5G), or energy expenditure (Fig 2-5H).
Figure 2-5: Body weight, body weight gain, and fat mass for LFABP$^{+/+}$ (●) and LFABP$^{int/−}$ (■) mice after 12 weeks of 45% Kcal HF feeding. A,B, Male mice 24-hour food intake (n=9-10); C, Male mice 24-hour respiratory exchange ratio (n=7-9); D, Male mice energy expenditure (n=7-9); E,F, Female mice 24-hour food intake (n=8-9); G, Female mice 24-hour respiratory exchange ratio (n=7); H, Female mice energy expenditure (n=7).
**LFABP^{int-/-} mice do not have alterations in plasma markers of energy balance**

Oral glucose tolerance tests were performed on 6 hour fasted HF fed LFABP^{fl/fl} and LFABP^{int-/-} mice after 12 weeks of HF feeding. There were no differences in blood glucose concentrations for the male mice at any time point (Fig 2-6A and B). Fasting plasma insulin (Fig 2-6C) and leptin levels (Fig 2-6D and E) also did not differ between the two groups. For female mice, like the male mice, no changes were observed in glucose tolerance (Fig 2-6F and G) or fasting plasma insulin (Fig 2-6H). Fasting plasma leptin was found to be higher in female LFABP^{int-/-} mice relative to female LFABP^{fl/fl} mice (Fig 2-6I), but a calculation of leptin index factoring in fat mass revealed no significant difference between these two groups (Fig 2-6J).
Figure 2-6: Blood analyses for LFABP^{fl/fl} (●) and LFABP^{int−/−} (■) mice after 12 weeks of 45% Kcal HF feeding. A, Male mice glucose tolerance test (n=8); B, Male mice glucose tolerance area under the curve (n=8); C, Male mice fasting plasma insulin (n=6-8); D, Male mice fasting plasma leptin (n=6-8); E, Female mice leptin index (n=6-8); F, Female mice glucose tolerance test (n=6-7); G, Female mice glucose tolerance area under the curve (n=6-7); H, Female mice fasting plasma insulin (n=6-7); I, Female mice fasting plasma leptin (n=6-7); J, Female mice leptin index (n=6-7).
*LFABP<sup>int-/-</sup> mice retain their exercise capacity following chronic HF feeding*

Both spontaneous and induced physical activity parameters were assessed in the male and female LFABP-cKO mice. An assessment of 24-hour spontaneous activity revealed no differences between male LFABP<sup>fl/fl</sup> and LFABP<sup>int-/-</sup> mice (Fig 2-7A). However, LFABP<sup>int-/-</sup> mice were found to have higher exercise endurance relative to the LFABP<sup>fl/fl</sup> mice, being able to run on the treadmill for a longer time (Fig 2-7B) and a farther distance (Fig 2-7C). Like their male counterparts, the female LFABP-cKO mice did not have alterations in spontaneous activity (Fig 2-7D), but female LFABP<sup>int-/-</sup> mice did also display higher exercise endurance relative to their LFABP<sup>fl/fl</sup> controls (Fig 2-7E and F).
Figure 2-7: Analyses of spontaneous of activity and endurance capacity for LFABP$^{fl/fl}$ (●) and LFABP$^{int/-}$ (■) mice after 12 weeks of 45% Kcal HF feeding. A, Male mice 24-hour spontaneous activity (n=10-11); B, Male mice exercise endurance running time (n=8); C, Male mice exercise endurance running distance (n=8); D, Female mice 24-hour spontaneous activity (n=8-9); E, Female mice exercise endurance running time (n=6-7); F, Female mice exercise endurance running distance (n= 6-7).
Discussion

In previous studies, feeding whole-body LFABP\(^{-/-}\) male mice a HF diet resulted in increased body weight, fat mass, and food intake relative to WT mice \(^{16}\). While LFABP\(^{-/-}\) mice become obese they appear to be metabolically healthy, being normoglycemic, normoinsulinemic, and also displaying reduced hepatic steatosis, and intestinal TG secretion rates similar to those of lean mice despite their obesity \(^{16,113,187,192}\). Additionally, HF fed LFABP\(^{-/-}\) mice are more active and have greater exercise endurance than WT mice \(^{16}\). While whole-body LFABP\(^{-/-}\) mice appear to be a model of the MHO phenotype, it is unknown if the phenotypes observed are due to liver-LFABP, intestinal-LFABP, or if the ablation of both is necessary. In order to assess the role of intestinal-LFABP in the observed whole-body phenotypic response to HF feeding, LFABP conditional knockout (cKO) were generated. In this study, the intestine-specific LFABP null mouse was examined in order to determine the role of intestinal LFABP in the phenotype of the whole body LFABP\(^{-/-}\).

Unlike the whole-body male LFABP\(^{-/-}\) mice, male LFABP\(^{int\,-/-}\) mice do not appear to become more obese in response to HF feeding. Their BW, BW gain, and body composition were similar to that of their WT-LFABP\(^{fl/fl}\) controls, and the WT controls of the previous HF feeding study \(^{16}\). While the obese phenotype of the LFABP\(^{-/-}\) mice can be partly explained by increased food intake, the LFABP\(^{int\,-/-}\) mice did not have any observable differences in amount of food consumed. It is likely that the lack of differences observed in BW and body composition are partly due to the fact that food intake was not altered as well. The lack of changes observed here suggests that the ablation of LFABP in the liver is needed as well to induce increased food intake, BW, and fat mass.

Indirect calorimetric assessments using the Oxymax system previously demonstrated that HF fed LFABP\(^{-/-}\) mice have lower average RERs and increased spontaneous activity when compared to their WT counterparts, implying LFABP\(^{-/-}\) mice relied more so on lipid for metabolic fuel \(^{16}\). Additionally, an assessment of exercise endurance revealed that LFABP\(^{-/-}\) mice, despite being more obese, were able to run on a treadmill for a longer period than WT mice \(^{16}\). Unlike the LFABP-
mice, male LFABP\textsuperscript{int/-} mice were found to have RER values comparable to their WT-LFABP\textsuperscript{fl/fl} controls, suggesting that the ablation of liver-LFABP is necessary to induce greater lipid usage at the whole-body level. Additionally, no changes were observed in spontaneous activity of the male LFABP-cKO mice.

While no alterations in spontaneous activity were observed, male LFABP\textsuperscript{int/-} mice retained their exercise capacity after chronic HF feed in response to an induced exercise bout, being able to run for a greater distance and period of time when compared to the LFABP\textsuperscript{fl/fl} mice. It had been hypothesized previously that LFABP\textsuperscript{-/-} mice might have better exercise endurance than WT mice because of their increased spontaneous activity. It was thought that this increase in activity might act as a self-induced form of chronic training, allowing the LFABP\textsuperscript{-/-} mice to be better adapted to potential exercise challenges. However, the increased exercise capacity of the LFABP\textsuperscript{int/-} mice does not support this notion, suggesting that the ablation of LFABP specifically in the intestine is able to influence exercise capacity. We have recently found that at rest the skeletal muscle of whole-body LFABP\textsuperscript{-/-} mice have increased glycogen stores and intramuscular TG (IMTG) levels, suggesting that LFABP\textsuperscript{-/-} mice have increased availability of carbohydrate and lipid substrates. Additionally, LFABP\textsuperscript{-/-} mouse skeletal muscle was observed to have increased FA oxidation and mitochondrial enzyme activity, which implies that there is increased substrate utilization occurring in LFABP\textsuperscript{-/-} skeletal muscle as well. Since LFABP is not expressed in the skeletal muscle, this suggests that there is interorgan cross talk occurring between tissues that express LFABP and skeletal muscle. Interestingly, moreover, there is evidence of cross talking occurring between the gut, skeletal muscle, and cardiac muscle that influences physiological responses to exercise or overnutrition. It is thought that this communication is bidirectional, being mediated by the microbiome and mitochondria. For example, some commensal bacteria are able to produce short chain fatty acids (SCFAs), which are able to modulate mitochondrial function, impacting energy production and mitochondrial biogenesis. Mitochondria, in turn, are
able to modify the activity of the microbiome by altering innate immune responses. Thus, it is feasible that the intestine specific ablation of LFABP, a protein that is normally highly abundant in the small intestine, can yield a phenotype in skeletal and/or cardiac muscle.

Aspects of whole-body metabolic signaling were previously assessed in HF fed male LFABP/mice. Despite being more obese, it was observed that LFABP/mice had fasting insulin levels similar to that of their leaner WT counterparts. It was also shown that HF fed LFABP/mice had elevated plasma leptin and leptin index values; low fat (LF) fed LFABP/mice, which were as lean as LF fed WT mice, also had elevated plasma leptin and leptin index values, indicating that the elevation of plasma leptin was intrinsic to the whole-body ablation of LFABP and not alterations in fat mass. Male LFABP/int/mice did not have elevated leptin levels or leptin index values, suggesting that the ablation of liver-LFABP is necessary for the elevated leptin phenotype to be present.

In contrast to these observations, and unlike what was observed for male LFABP/int/mice, female LFABP/int/mice gained more weight and had greater fat mass when compared to female LFABP/fl/fl mice. Despite these alterations in BW and body composition, no differences were observed in food intake, RER, or energy expenditure. It is possible that, instead, these changes are induced by altered intestinal transit of nutrients. We have recently found that whole-body HF fed LFABP/mice have decreased total fecal output and slower intestinal transit times (unpublished data), which may partly explain their obese phenotype as well. A longer intestinal transit time would provide more time for digestive enzymes to interact with chyme in the small intestine, which may lead to more efficient or complete nutrient absorption. It remains to be determined whether or not the transit phenotype is also present in the female LFABP/int/mice.

Aside from differences in BW and body composition, the phenotypic observations made in the female LFABP-cKO mice were similar to that of the male LFABP-cKO mice. While no differences were observed for glucose tolerance or fasting plasma insulin, female LFABP/int/mice were found
to have higher fasting leptin levels. However, once fat mass was factored in there were no longer significant differences between the female WT and KO mice. Additionally, while spontaneous activity did not differ between female LFABP\textsuperscript{int}\textsuperscript{-/-} and LFABP\textsuperscript{int}\textsuperscript{-/-} mice, it was observed that the LFABP\textsuperscript{int}\textsuperscript{-/-} mice also retained their exercise capacity in response to chronic HF feed, having greater running endurance when compared to LFABP\textsuperscript{fl/fl} mice. This suggests that, unlike the body composition phenotype, the exercise endurance phenotype is not gender dependent, and only requires the ablation of intestinal-LFABP.

Others have assessed obesity-related phenotypes in female LFABP\textsuperscript{-/-} mice. In the hands of one group in St. Louis, female LFABP\textsuperscript{-/-} mice fed a 41% Kcal butter fat HF diet were found to be resistant to induced obesity and the development of hepatic steatosis\textsuperscript{187,217}. However, a group in Texas demonstrated that female LFABP\textsuperscript{-/-} gained more weight when challenged with a HF diet\textsuperscript{190}. Additionally, female LFABP\textsuperscript{-/-} mice maintained on standard chow were more prone to obesity in response to aging\textsuperscript{188}. However, the St. Louis group found that under similar conditions, female LFABP\textsuperscript{-/-} mice were resistant to age induced obesity\textsuperscript{113}. As mentioned above, the St. Louis LFABP\textsuperscript{-/-} mice tend to gain less weight than WT in response to different challenges, while the Texas mice and our mice become obese\textsuperscript{11,16,113,186,188}. Differences may be attributable to differences in gene knockout strategies, background strain, or the gut microbiome. Despite the differences in weight gain responses, however, the St. Louis LFABP\textsuperscript{-/-} and Texas LFABP\textsuperscript{-/-} lines share many similarities, including defective hepatic FA uptake, oxidation, and VLDL secretion\textsuperscript{161,185,187,190}. We have not previously assessed female whole-body LFABP\textsuperscript{-/-} mice. Given differences observed in the female LFABP\textsuperscript{int}\textsuperscript{-/-} mice, it is of interest to pursue similar studies in HF fed female LFABP\textsuperscript{-/-} mice.

Many of the phenotypes observed in the HF fed male LFABP\textsuperscript{-/-} mice were not present in HF fed male LFABP\textsuperscript{int}\textsuperscript{-/-} mice. It is possible that phenotypic changes, such as the obesity, elevated leptin, and alterations in RER require either the ablation of liver-LFABP alone or the simultaneous
ablation of bother liver- and intestine-LFABP. Studies of liver-specific LFABP^{+/-} mice (LFABP^{Liv+/-}) are underway to help determine the tissue specific origins of the MHO phenotype observed in the male LFABP^{+/-} mice. Additionally, since differences were observed in the response of male and female LFABP^{int+/-} mice to HF feeding, it will be important to determine the sex specific interactions that may influence, or be influenced by, the presence or absence of LFABP.
Chapter 3

Mechanisms Underlying Reduced Weight Gain in Intestinal Fatty Acid-Binding Protein (IFABP) Null Mice
**Abstract**

Intestinal-fatty acid binding protein (IFABP; FABP2) is a 15 kDa intracellular protein abundantly present in the cytosol of the small intestinal enterocyte. High fat (HF) feeding of IFABP−/− mice resulted in reduced weight gain and fat mass relative to wild-type (WT) mice. Here, we examined intestinal properties that may underlie the observed lean phenotype of high fat-fed IFABP−/− mice. No alterations in fecal lipid content were found, suggesting that the IFABP−/− mice are not malabsorbing dietary fat. However, the total excreted fecal mass for the IFABP−/− mice was increased relative to WT mice. Moreover, we found reduced intestinal transit time in the IFABP−/− mice. IFABP−/− mice were observed to have a shortened average villus length, a thinner muscularis layer, reduced goblet cell density, and reduced Paneth cell abundance. The number of proliferating cells in the crypts of IFABP−/− mice did not differ from that of WT mice, suggesting that the blunt villi phenotype is not due to alterations in proliferation. IFABP−/− mice were observed to have altered expression of genes related to intestinal structure, while immunohistochemical analyses revealed increased staining for markers of inflammation. Taken together, the ablation of IFABP leads to changes in gut motility and morphology which likely contribute to the relatively leaner phenotype occurring at the whole-body level. Thus, these results suggest that IFABP is likely involved in dietary lipid sensing and signaling, influencing intestinal motility, intestinal structure, and nutrient absorption, thereby impacting systemic energy metabolism.
**Introduction**

The small intestine is the primary site of dietary lipid absorption, where the absorptive enterocytes are responsible for processing the hydrolysis products of dietary lipids. Though dietary triacylglycerol (TG) content is particularly high in Western diets, absorption from the lumen of its hydrolysis products, fatty acid (FA) and monoacylglycerol (MG), is highly efficient, with greater than 95% of dietary lipid taken up\(^1\)\(^,\)\(^3\)\(^,\)\(^3\). Intracellular carrier proteins are thought to be required for efficient trafficking of these hydrophobic lipid species within the hydrophilic cytoplasmic milieu, although this has not been definitively shown. The intestinal-fatty acid binding protein (IFABP; FABP2) is a member of the FABP family, a group of 14-15 kDa intracellular proteins that are present in high abundance (1-5%) in the cytosol of most tissues\(^1\)\(^,\)\(^1\)\(^2\)\(^,\)\(^1\)\(^2\)\(^6\). Like other members of the FABP family, IFABP has a high affinity for long-chain fatty acids (LCFAs)\(^1\)\(^4\)\(^4\) and *in vitro* studies have shown that IFABP transfers FAs to membranes via a collisional mechanism that is typical of most members of the FABP family\(^1\)\(^4\)\(^7\). Several *in vitro* and *ex vivo* studies have suggested that IFABP is involved in enterocyte uptake of FA from both the intestinal lumen and the bloodstream\(^1\)\(^4\)\(^8\),\(^1\)\(^8\)\(^4\). However, a number of studies in animal models lacking IFABP have found that FA uptake is not impaired\(^1\)\(^5\),\(^1\)\(^6\),\(^1\)\(^9\)\(^1\).

We previously showed that on a 45% Kcal fat high fat diet (HFD) IFABP\(^-\)\(^/-\) mice remained lean when compared to WT mice, displaying reduced body weight (BW), BW gain, and lower fat mass percentage\(^1\)\(^6\). Food intake was significantly lower in the IFABP\(^-\)\(^/-\) mice, but food efficiency calculations indicated that the observed decrease in BW of the IFABP\(^-\)\(^/-\) mice could not be fully explained by the decrease in food intake\(^1\)\(^6\). Since, as noted above, the enterocyte FABPs have long been thought to be involved in dietary lipid uptake and assimilation\(^1\)\(^1\), it is tempting to speculate that mice lacking IFABP might malabsorb lipid, thus explaining their observed lean phenotype. Fecal lipid content did not vary between groups, however, suggesting that the IFABP\(^-\)\(^/-\) mice were not malabsorbing lipid\(^1\)\(^6\). As it is possible that the lipid content of the 45% Kcal HFD
is not sufficient to stress the absorptive capacity of the small intestinal enterocytes, in the present studies we examined fecal fat in mice fed a supraphysiological 60% Kcal fat diet. In addition, we determined not only fecal lipid content, but also the small intestinal localization of FA absorption along the proximal to distal axis, total fecal excretion, and the intestinal transit time of mice fed the 45% Kcal HFD.

During organ collection, it was observed that the intestinal tissue of the HF fed IFABP−/− mice seemed to be more fragile than that of WT mice. We, therefore, hypothesized that the ablation of IFABP may lead to alterations in intestinal structure and, perhaps, inflammation. Thus, gene expression, histological, and immunohistochemical analyses were performed to assess small intestinal integrity and inflammatory status. Additionally, we assessed small intestine goblet cell density, since mucus production by the goblet cells is important for intestinal integrity 41. We also examined Paneth cell density, as Paneth cells secrete antimicrobial peptides and other molecules that regulate cell proliferation and differentiation 44.

The results showed no differences, relative to WT mice, in the fecal lipid content of IFABP−/− mice, even when challenged with the 60% Kcal HFD. Interestingly, however, HF fed IFABP−/− mice were found to have increased total fecal excretion and reduced energy absorption, which was explained, at least in part, by a more rapid intestinal transit rate. Additionally, IFABP−/− mice were found to have altered expression of genes encoding intestinal structural markers and markers of ER stress, shorter proximal small intestinal villi, a thinner muscularis layer, a reduction in Paneth cell abundance, and a reduced goblet cell density. Collectively, these changes in the IFABP−/− intestinal mucosa indicate a heretofore unappreciated role for IFABP in intestinal motility and integrity, and suggests that reduced weight gain is secondary to increased fecal excretion of lipids, and likely, other nutrients.
**Experimental Procedures**

**Animals and Diets**

As previously reported, the IFABP<sup>−/−</sup> mice used in this study are a substrain bred by intercrossing of an original strain of IFABP<sup>−/−</sup> mice and are congenic on a C57BL/6J background<sup>15,128,191</sup>. C57BL/6J mice from The Jackson Laboratory (Bar Harbor, ME) were bred as wild-type (WT) controls. Mice were housed 2-3 per cage unless specified otherwise, maintained on a 12-hour light/dark cycle, and allowed *ad libitum* access to standard rodent chow (Purina Laboratory Rodent Diet 5015). At 2 months of age, male WT and IFABP<sup>−/−</sup> mice were fed either a 45% Kcal fat high fat diet (HFD) (D10080402; Research Diets, Inc., New Brunswick, NJ), a 60% Kcal HFD (D04051705; Research Diets), or a 10% Kcal fat low fat diet (LFD) (D10080401; Research Diets) as indicated. Body weights (BW) were measured weekly for a period of 12 weeks. Fat mass measurements were taken by MRI (Echo Medical Systems, LLC., Houston, TX) 2-3 days prior to starting the feeding protocol, and 2-3 days prior to sacrifice. The instrument was calibrated each time according to the manufacturer’s instructions. At each time point, two measurements were taken for each mouse and averaged.

**Preparation of Tissue and Plasma**

Mice were fasted for 16 hours prior to sacrifice unless otherwise stated. At sacrifice blood was drawn; plasma was isolated after centrifugation for 6 minutes at 4000 rpm, and stored at -80°C. Epididymal fat pads and livers were removed, immediately placed on dry ice, and stored at -80°C for further analysis. The small intestine from the pyloric sphincter to the ileocecal valve was removed, measured lengthwise, rinsed with 60mL of ice-cold 0.1M NaCl, and opened longitudinally. Intestinal mucosa was scraped with a glass microscope slide into tared tubes on dry ice and stored for future use.
RNA Extraction and Real-Time PCR

Total mRNA was extracted from small intestinal mucosa and analyzed as previously described. Primer sequences were obtained from Primer Bank (Harvard Medical School QPCR Primer Database) and are shown in Table 1. The efficiency of PCR amplifications was analyzed for all primers to confirm similar amplification efficiency. Real time PCRs were performed in triplicate using an Applied Biosystems 7300 instrument. Each reaction contained 80ng of cDNA, 250nM of each primer, and 12.5μL of SYBR Green Master Mix (Applied Biosystems, Foster City, CA) in a total volume of 25μL. Relative quantification of mRNA expression was calculated using the comparative Ct method, normalized to TATA-binding protein (TBP). Primer sequences for the genes that were analyzed are shown in Table 1.

Western Blot Analysis

Small intestinal mucosa was harvested as described above, and homogenized in 10x volume of PBS pH 7.4 with 0.5% (vol/vol) protease inhibitors (Sigma 8340) on ice with a Potter Elvejhem homogenizer. Total cytosolic fractions were obtained by ultracentrifugation (100,000g, 1 hour at 4°C) and protein concentration determined by Bradford assay. Thirty micrograms of cytosolic protein was mixed with an Instant-Bands pre-stained protein sample loading buffer in a 2:1 (v/v) ratio (EZBiolab, Carmel, IN) to allow for visualization of total sample protein. Samples were loaded onto 15% polyacrylamide gels and separated by SDS-PAGE. The proteins were transferred onto 0.45μm nitrocellulose membranes using a semidry transfer system (Bio-Rad) for 1 hour and 45 minutes at 23 V. Membranes were blocked by incubating in 5% nonfat dry milk overnight at 4°C, and were incubated with a primary antibody of either α-LFABP (1:2000 for 1 hour at room temperature) or α-IFABP (1:10,000 for 1 hour at room temperature; generous gift from B. Corsico, U. La Plata). For assessing phosphorylated and total eIF2α, membranes were blocked in 5% milk for 1 hour at room temperature, and then incubated with either α-phospho(S51)-eIF2α (1:5000, Cell Signaling Technology, CST 3597) or α-eIF2α (1:5000, Santa Cruz, sc-11386)
overnight at 4°C\textsuperscript{218}. After thorough washing, blots were incubated in \(\alpha\)-rabbit IgG-horseradish peroxidase conjugate (1: 20,000) for 1 hour, and developed by chemiluminescence (WesternBright Quantum, Advansta, Menlo Park, CA). Protein expression was quantified by densitometric analysis with LI-COR Image Studio (Lite version 5.2). Target protein content was normalized to total protein content within a sample.

\textit{Fecal Lipid Content}

During the 12-week high fat feeding periods, feces were collected between weeks 10 and 12 of the feeding protocol, and subsequently dried at 60°C for 3 days. 0.5g (dry weight) of feces was dissolved in water overnight, and lipids extracted using the Folch method\textsuperscript{219}. The extracted lipids in 2:1 chloroform/methanol (v/v) were placed in pre-weighed glass tubes, dried down completely under a nitrogen stream, and recovered lipid mass determined by weight difference. The weight of the extract was divided by the original dry weight of the feces to determine the percent fecal lipid.

\textit{Fat Absorption Localization Experiment}

The protocol described by Nelson et al. was modified to perform fat absorption localization experiments\textsuperscript{220}. In short, following a 4.5 hour fast, mice were gavaged with 8 \(\mu\)Ci of \(^3\)H-labeled TG in 200\(\mu\)L olive oil. The mice were then anesthetized 1.5 hour after the gavage and the small intestine was excised, rinsed with 0.85% NaCl, and then cut into 2 cm sections. The intestinal sections were digested overnight in 500\(\mu\)L of 1 M NaOH at 60°C. The next day 300\(\mu\)L of 1 N HCl was added to quench, and the radioactivity of each section was measured in a scintillation counter.

\textit{Intestinal Transit Time}

Individually housed mice were allowed \textit{ad libitum} access to food and water. After two hours of acclimation, mice were given 200\(\mu\)L of 6% carmine red and 0.5% methylcellulose (Sigma-Aldrich,
St. Louis, MO) in PBS by oral gavage. The cages were inspected every 10 minutes post gavage, and the time of appearance of the first red fecal pellet was recorded \(^{221,222}\).

**Total Fecal Excretion**

Mice were housed 2-3 per cage. Feces from each cage were collected every 3-4 days, and subsequently dried overnight and weighed. The weight of the feces was divided by the number of mice in the cage, and by the number of days of collection. To control for differences in food intake, the results for each genotype were normalized to their respective 24-hour food intakes, to generate values of g feces excreted/g consumed/mouse/day.

**Bomb Calorimetry**

Fecal energy content was assessed using a microbomb calorimeter (Parr) with a benzoic acid standard. Briefly, 6 fecal pellets were homogenized in 2mL water to form a uniform slurry. Fecal samples were then frozen at -80°C. Thawed samples were lyophilized and each sample was used to form 2 uniform pellets with a pellet press. Each pellet was separately loaded into the microbomb calorimeter for caloric density assessment. Each pellet represented one measure per sample, allowing for samples to be measured in duplicate. Energy absorbed was determined by calculating the energy ingested from the semi-purified HF diet/24h minus the energy excreted in the feces/24h.

**Plasma Endotoxin Analysis**

Plasma endotoxin levels were assessed using a Pierce™ LAL Chromogenic Endotoxin Quantitation Kit (Cat no. 88282, ThermoFisher Scientific), according to manufacturer’s instructions. Samples were run in triplicate and averaged to provide a plasma endotoxin value for each mouse.
**FITC-Dextran Intestinal Permeability Assay**

Intestinal permeability was assessed by a modified version of the protocol described by Wotin and Blaut \(^{216}\). Briefly, after a 6 hour fast, mice were orally gavaged with 150 μL of fluorescein isothiocyanate (FITC)–dextran (100 mg/mL) (Cat no. 60842-46-8, Millipore Sigma). Four hours post-gavage, mice were sacrificed and whole blood was collected. Serum was isolated by centrifugation and kept in the dark at room temperature for 30 minutes prior to analysis. A standard curve was developed on a 96-well plate using FITC-dextran concentrations in a range between 100 μg/mL to 1 μg/mL. Fluorescence intensities of the standards and samples were then measured using an excitation of 485nm and emission of 528nm. Following blank subtraction, sample FITC concentrations were determined based on the standard curve, in ug/ml.

**Histochemical and Immunohistochemical (IHC) Analyses**

Small intestines were removed as described above. The first 6\(^{th}\) of the SI, representing the proximal SI, was isolated, rinsed with a cold 0.85% sodium chloride solution, opened longitudinally, Swiss rolled, and fixed overnight at 4°C in 3% paraformaldehyde (PFA) and 2% sucrose in phosphate buffered saline. Tissues were then embedded in paraffin. For initial histological analysis, 5μm intestinal tissue sections were stained with hematoxylin and eosin (H&E) (Rutgers Pathology Services, Piscataway, NJ). Average villus length was assessed by dividing H&E stained Swiss roll sections into 5 quadrants and measuring 20 villi per quadrant, for a total of 100 villi measured per animal. To assess average muscularis thickness, 80 separate measurements were recorded for each animal. These were averaged to provide a value specific to that mouse. Goblet cells were enumerated using periodic acid-Schiff (PAS)/Alcian blue, which stained acidic and neutral mucins, respectively. Goblet cell count was normalized to villus length, allowing for goblet cell density to be determined. For the visualization of Paneth cells, phloxine-tartrazine staining was performed (Lendrum’s stain kit; Cat no. ES9540, ThermoFisher Scientific). For IHC studies, 5μm intestinal sections were deparaffinized, rehydrated, and blocked with 100%
normal goat serum at room temperature for 2 hr. The tissue sections were then incubated overnight at 4°C with a primary rabbit polyclonal COX-2 antibody (1:500, Abcam, Cambridge, MA), mucin 2 antibody (1:100, Abcam), iNOS antibody (1:100, Abcam), Claudin 2 antibody (1:200, Abcam), Claudin 5 antibody (1:200, Abcam), or mouse polyclonal MCP1 antibody (1:200, Abcam). Tissue sections were then incubated for 30 min with a either a biotinylated goat anti-rabbit secondary antibody (1:10000, Vector Labs, Burlingame, CA) or biotinylated horse anti-mouse secondary antibody (1:10000, Vector Labs). Antibody binding was visualized using a DAB Peroxidase Substrate Kit (Vector Labs). Tissue sections were scanned using the VS120-L100 Olympus virtual slide microscope (Waltham, MA).

Bromodeoxyuridine Assays

Proliferation was assessed by measuring the incorporation of bromodeoxyuridine (BrdU). Mice were injected with 200μL of BrdU (BD Biosciences) intraperitonially 2 hours or 48 hours prior to sacrifice. Small intestines were removed, Swiss rolled and fixed overnight at 4°C in a 3% PFA solution. IHC staining for BrdU was then performed using an anti-BrdU antibody (1:400; BD Biosciences). Tissue sections were then incubated for 30 min with a biotinylated horse anti-mouse secondary antibody (1:10000, Vector Labs, Burlingame, CA). Antibody binding was visualized using a DAB Peroxidase Substrate Kit (Vector Labs).

Statistical Analysis

All group data are shown as average ± SEM. Statistical comparisons were determined between genotypes on the same diet using a two-sided Student’s t-test. Differences were considered significant for P<0.05.
**Table 1:** Primer sequences used for qPCR analyses.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBP-F</td>
<td>5'-CAAAACCAGAATTGTTCTCCTT-3'</td>
<td></td>
</tr>
<tr>
<td>TBP-R</td>
<td>5'-ATGTGGTCTTCTGCTGACCT-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin1-F</td>
<td>5'-GCCTTGTAGGTAAATTGCATCC-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin1-R</td>
<td>5'-GGGCACATATGTCGCGCAGAC-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin2-F</td>
<td>5'-AGTACCTTTTTAGACTTCCTGC-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin2-R</td>
<td>5'-CCCACCACAGATAATAACAGC-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin3-F</td>
<td>5'-ACCAACTGTGTCACAGACAG-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin3-R</td>
<td>5'-CGGCCACCAACGGGTTATAG-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin4-F</td>
<td>5'-ATGGCGTCTATGGGACTACAG-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin4-R</td>
<td>5'-GAGCGCAACTCAGGATG-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin5-F</td>
<td>5'-GCCAGGTGTATGAATCTGTGCT-3'</td>
<td></td>
</tr>
<tr>
<td>Claudin5-R</td>
<td>5'-GCAAGGTTATATCGTCTGCT-3'</td>
<td></td>
</tr>
<tr>
<td>CDH1-F</td>
<td>5'-CAGGTCTCCTCATGGCTTTGC-3'</td>
<td></td>
</tr>
<tr>
<td>CDH1-R</td>
<td>5'-CTTCCGAAAAGAAGGCTGTCC-3'</td>
<td></td>
</tr>
<tr>
<td>Occludin-F</td>
<td>5'-ACCCGAAGAAAGATGGGATG-3'</td>
<td></td>
</tr>
<tr>
<td>Occludin-R</td>
<td>5'-CATAGTCAGATGGGGGTGGA-3'</td>
<td></td>
</tr>
<tr>
<td>ZO1-F</td>
<td>5'-TGGGAACAGACACAGATGAC-3'</td>
<td></td>
</tr>
<tr>
<td>ZO1-R</td>
<td>5'-GCTGCGCCTCCTTAAACAC-3'</td>
<td></td>
</tr>
<tr>
<td>JAMA-F</td>
<td>5'-CTGATCTTTAGCCGCTGAC-3'</td>
<td></td>
</tr>
<tr>
<td>JAMA-R</td>
<td>5'-ACCAACGCAGAAAATCAAG-3'</td>
<td></td>
</tr>
<tr>
<td>Beta Actin-F</td>
<td>5'-GGCTGTATTCCCCTCCATCG-3'</td>
<td></td>
</tr>
<tr>
<td>Beta Actin-R</td>
<td>5'-CCAGTGGTTAACAATGCCATGT-3'</td>
<td></td>
</tr>
<tr>
<td>LFABP-F</td>
<td>5'-GGGGGTTGTCAGAAATCTG-3'</td>
<td></td>
</tr>
<tr>
<td>LFABP-R</td>
<td>5'-CAGCTTTGACGACTGCCTTG-3'</td>
<td></td>
</tr>
<tr>
<td>IFABP-F</td>
<td>5'-GTGGAAAGTAGACCGGAAACGA-3'</td>
<td></td>
</tr>
<tr>
<td>IFABP-R</td>
<td>5'-CCATCTCTGTTGATTTGTCAGT-3'</td>
<td></td>
</tr>
<tr>
<td>HFABP-F</td>
<td>5'-ACCTGGAAGCTGAGTGACAG-3'</td>
<td></td>
</tr>
<tr>
<td>HFABP-R</td>
<td>5'-TGATGTTAGTTAGGCTTGCTG-3'</td>
<td></td>
</tr>
<tr>
<td>AFABP-F</td>
<td>5'-AAGGTGTTAGAGTGACCATCATAC-3'</td>
<td></td>
</tr>
<tr>
<td>AFABP-R</td>
<td>5'-TCAGCCTTTCTACACATACCC-3'</td>
<td></td>
</tr>
<tr>
<td>KFABP-F</td>
<td>5'-TGAAGAGCTAGTGGAGCTAGCTG-3'</td>
<td></td>
</tr>
<tr>
<td>KFABP-R</td>
<td>5'-CTCTCGGTGGTTGAGCTGATG-3'</td>
<td></td>
</tr>
<tr>
<td>ILBP-F</td>
<td>5'-CTTCCAGAGCAGCTGATTGAAA-3'</td>
<td></td>
</tr>
<tr>
<td>ILBP-R</td>
<td>5'-CCTCCGAAGTCTGGTGATAGTG-3'</td>
<td></td>
</tr>
</tbody>
</table>
Results

IFABP$^{-/-}$ mice remain lean on supraphysiologic high fat diets

At 8 weeks of age, prior to the start of HF feeding, IFABP$^{-/-}$ and WT mice had similar BW, fat mass, and fat free mass (data not shown). As previously demonstrated $^{16}$, after 12 weeks of 45% Kcal HF feeding, IFABP$^{-/-}$ mice gain less weight and remain lean when compared to WT mice (Fig 3-1). When challenged with a supraphysiologic 60% Kcal HFD for 12 weeks the same pattern is observed, with IFABP$^{-/-}$ mice still gaining less weight and remaining leaner than WT mice (Fig 3-1).

Ablation of IFABP does not cause compensatory upregulation of LFABP in HF diet-fed mice

The expression of LFABP in response to ablation of IFABP was assessed after 12 weeks of 45% Kcal fat high fat feeding. As was observed previously for mice fed a low-fat chow diet, IFABP$^{-/-}$ mice do not have increased LFABP mRNA or protein levels relative to WT mice (Fig 3-2A and B). Additionally, we found no compensatory upregulation of the distal small intestinal FABP, ileal FABP (ILBP, FABP6); other FABPs that are not typically expressed within the SI were also not observed in either WT or IFABP$^{-/-}$ intestine from the HF-fed mice (Fig 3-2A).
Figure 3-1: Body weight and fat mass for WT (●) and IFABP−/− (■) mice after 12 weeks of 45% Kcal or 60% Kcal fat feeding. A, body weights on 45% Kcal fat (n=10) or 60% Kcal fat HFD (n=6-7); B, body fat percentage on 45% Kcal fat (n=10) or 60% Kcal fat HFD (n=6-7).
Figure 3-2: mRNA expression and protein levels of proximal small intestine FABPs in WT (●) and IFABP−/− (■) mice after 12 weeks of 45% Kcal HFD. A, relative gene expression of FABP family members (n=5-12); B, the top panels are Western blot membranes blotting for either LFABP (left) or IFABP (right). The bottom panels show the total protein content of the Western membranes. PLF, purified LFABP, PIF, purified IFABP; C, relative protein levels of IFABP or LFABP (n=8). Purified LFABP (pLF) and Purified IFABP (pIF) were loaded as positive controls for the Western blots.
Mice lacking IFABP have increased fecal mass, reduced energy absorption, and rapid intestinal transit.

Consistent with previous observations, IFABP−/− mice do not appear to malabsorb lipid on a 45% Kcal HF diet, based on fecal fat content (Fig 3-3A). Similarly, in mice challenged with the very high 60% Kcal fat diet, no differences in fecal fat content were noted between IFABP−/− and WT mice (Fig 3-3A). Additionally, no shift in [3H]-FA uptake along the proximal to distal axis of the small intestine was observed in mice challenged with the 45% Kcal HFD (Fig 3-3B). Interestingly, however, analysis of total fecal mass showed that 45% Kcal HF fed IFABP−/− mice have a significant increase in total fecal excretion, controlling for total food intake (Fig 3-3C). Further, the IFABP−/− mice had significantly shorter intestinal transit times, indicating that nutrients moved from mouth to anus more rapidly (Fig 3-3D). Together these data imply that the IFABP−/− mice are, indeed, absorbing less lipid than WT mice. Moreover, they may be absorbing less of other nutrients as well; as evidenced by the increase in fecal mass without a change in fecal fat content. This was confirmed by bomb calorimetric assessment of fecal caloric density, which revealed that there were no differences between WT and IFABP−/− mice (Fig 3-3E). Indeed, since IFABP−/− mice ingest less calories per day and secrete the same amount of calories per day in their feces, they have a net reduction in energy that is absorbed from the diet when compared to their WT counterparts. The rapid transit time, increased fecal excretion, and reduced energy absorption suggest that IFABP may play a role in the regulation of intestinal motility and, hence, in lipid and nutrient absorption.
Figure 3-3: Fecal lipid content, fat absorption localization, total fecal output, and intestinal transit times in WT (●) and IFABP−/− (■) mice after 12 weeks of HF feeding. A, fecal lipid percentage from 45% Kcal HF fed WT and IFABP−/− mice (n=8) and fecal lipid percentage from 60% Kcal HF fed WT and IFABP−/− mice (n=6). B, localization of intestinal lipid absorption 1.5 hours after oral gavage of [3H]TG in olive oil in mice fed the 45% Kcal HFD (n=6-8). C, daily food intake and fecal excretion in WT and IFABP−/− mice fed the 45% Kcal HFD, and fecal excretion normalized for intake (n=6). D, intestinal transit time in WT and IFABP−/− mice fed the 45% Kcal HFD (n=8-13). E, daily energy intake and energy absorption (accounting for energy excretion) in WT and IFABP−/− mice fed the 45% Kcal HFD (n=8).
Alterations in small intestine morphology and structure

IFABP\(^{-}\) mice were found to have a 7% shorter small intestine length when compared to WT mice (Fig 3-4A) \((p< 0.05)\), however when normalized to average BW, IFABP\(^{-}\) mice have an 8% longer SI for their size, relative to WT mice (Fig 3-4B) \((p<0.05)\). Analysis of H&E stained sections revealed that the proximal small intestinal villi of HF-fed IFABP\(^{-}\) mice are 39% shorter than the villi of WT mice (Fig 3-5) \((p< 0.01)\). In addition to having shortened villi, IFABP\(^{-}\) mice were also found to have a thinner muscularis layer (Fig 3-5). Alcian blue/PAS staining revealed that IFABP\(^{-}\) mice have significantly fewer small intestinal goblet cells than WT mice, and when normalized to average villus length, a reduced goblet cell density (Fig 3-5) \((p< 0.01)\). In addition to having a reduced goblet cell density, Lendrum’s staining revealed that the other major secretory cells of the small intestine, Paneth cells, were also in low abundance in IFABP\(^{-}\) mice (Fig 3-5).
Figure 3-4: Average length of small intestine in WT (●) and IFABP−/− (■) mice that have been fed a 45% Kcal HFD for 12 weeks. A, average small intestine length in HF fed WT and IFABP−/− mice. B, average small intestine length normalized to the average body mass in HF fed WT and IFABP−/− mice (n=12).
Figure 3-5: Small intestinal structure in 45% Kcal HF fed WT (●) and IFABP⁻/⁻ (■) mice. AB, Hematoxylin and eosin (H&E) stained small intestinal tissue sections (6.6X). CD, Periodic acid-Schiff (PAS)/Alcian blue used to visualize goblet cells (8X). The arrows point to positive staining for mucins. EF, Lendrum’s stain used to visualize secretory Paneth Cells (40X) The arrows point to positive staining for the acidophilic granules of the Paneth cells. G, average villus length of proximal small intestinal villi. H, average muscularis thickness in proximal small intestine. I, average goblet cell density in proximal small intestine. (n=3).
Mice null for IFABP have increased incidence of cell death in proximal small intestine

While both goblet cell staining and Paneth cell staining revealed a reduced amount of those specific cell types, a BrdU proliferation assay where mice were gavged with BrdU 2 hours prior to excision indicated that the amount of proliferating cells in the crypts was not significantly different between IFABP+/− mice and WT mice (Fig 3-6). However, 48 hours after gavage with BrdU IFABP−/− mice were found to have less BrdU positive cells in their villi when compared to WT mice. While the whole villus of the IFABP+/− stained positively for BrdU, WT mice displayed unstained cells towards the tips of their villi, with the middle and lower portions of their villi staining positively for BrdU (Fig 3-6). The positive staining in tissue collected from mice 2 hours post BrdU is considered representative of actively proliferating cells, while the positive staining associated with tissue collected from mice 48 hours post gavage is considered to be more representative of cell migration up the villus tips.
Figure 3-6: BrdU staining for 2h or 48h in the small intestinal crypts and villi of WT (●) and IFABP−/− (■) mice fed a 45% Kcal HFD for 12 weeks. A-B, Small intestinal sections from mice 2 hours post-BrdU injection stained with anti-BrdU (20X). Arrows point to positive staining. C, quantification of BrdU positive cells and total cells in the crypt. 50 crypts were assessed per animal (n=3). D-E, Small intestinal sections from mice 48 hours post-BrdU injection stained with anti-BrdU (4X). F, quantification of BrdU positive and total cells in the villus. 15 villi were assessed per animal (n=3).
Mice null for IFABP have increased intestinal permeability

Intestinal permeability was assessed in two ways. Plasma endotoxin (lipopolysaccharide or LPS) levels were analyzed as an indirect measure of intestinal permeability, and it was found that HF fed IFABP−/− mice have similar plasma endotoxin levels as their obese WT counterparts (Fig 3-7A). A direct assessment of permeability using a fluorescein isothiocyanate (FITC)–dextran assay demonstrated that IFABP−/− mice have increased intestinal permeability relative to WT mice (Fig 3-7B).
Figure 3-7: Assessments of intestinal permeability in WT (●) and IFABP<sup>−/−</sup> (■) mice fed a 45% Kcal HFD for 12 weeks. A, Plasma endotoxin is expressed in endotoxin units (EU) per milliliter (n=8). B, Serum FITC-dextran levels in mice 4 hours after gavage (n=3-6).
Alterations in expression of tight junction genes, markers of inflammation, and markers of ER stress

qPCR analysis was used to assess small intestinal structure, inflammation, and ER stress, revealing that IFABP\(^{-/-}\) mice have a 56% increased expression of claudin 2, a gene associated with a pore forming tight junction (TJ) protein, and 57% decreased expression of claudin 5, a gene associated with a tightening TJ protein (Fig 3-8A) \((p < 0.05)\). Both increased claudin 2 expression and decreased claudin 5 expression are associated with increased intestinal permeability. At the level of gene expression, it was found that IFABP\(^{-/-}\) mice have increased expression of caspase 3 \((p < 0.01)\) and activating transcription factor 6 (ATF6) \((p < 0.05)\), both of which are markers of ER stress and apoptosis (Fig 3-8B). Interestingly, while the abundance of mucin producing goblet cells was significantly lower in the small intestine of IFABP\(^{-/-}\) mice, gene expression for mucin 2, the most abundant mucin produced by small intestinal goblet cells, was similar to that of WT mice (Fig 3-8B). However, IHC analysis of mucin 2 showed reduced staining in IFABP\(^{-/-}\) mice, indicating a reduced abundance of mucin 2 protein (Fig 3-9). Additionally, in agreement with the directional changes observed at the level of gene expression, claudin 2 staining was increased and claudin 5 staining was decreased in the HF fed IFABP\(^{-/-}\) mice (Fig 3-9). Staining for monocyte chemoattractant protein 1 (MCP1), a marker of inflammation, endoplasmic reticulum (ER) stress, and immune cell infiltration, was increased in IFABP\(^{-/-}\) mice (Fig 3-10). Further, IHC staining for inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2), which are also markers of inflammation and ER stress, showed increased expression in IFABP\(^{-/-}\) mice when compared to WT mice (Fig 3-10). However, when the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2\(\alpha\)), another marker of ER stress, was assessed, no difference was found between groups (Fig 3-10).
Figure 3-8: Relative quantitation of mRNA expression of genes related to small intestinal structure and inflammation in 45% Kcal fat HF fed WT (●) and IFABP−/− (■) mice. A, structure-related genes. B, inflammation-related genes (n=8-12).
Figure 3-9: Assessment of small intestinal structure in 45% Kcal fat HF fed WT (●) and IFABP−/− (■) mice. A–F, Proximal small intestine sections stained with either anti-MUC2, anti-Claudin 2, or anti-Claudin 5 antibodies. Arrows point to positive staining (n=3).
Figure 3-10: Assessment of small intestinal inflammation and ER stress in 45% Kcal fat HF fed WT (●) and IFABP−/− (■) mice. A-F, Proximal small intestine sections stained with either anti-COX2, anti-iNOS, or anti-MCP1 antibodies. Arrows point to positive staining (n=3). G, Western blot showing phosphorylated eIF2α and total eIF2α (n=6). H, Relative quantification of phosphorylated eIF2α normalized to total eIF2α (n=6).
Some phenotypes observed in HF fed IFABP\(^{-/-}\) mice are influenced by dietary fat content

Since the above-described phenotypes found in the IFABP\(^{-/-}\) mice were found in HF diet-fed animals, we wondered whether the effects were due solely to the ablation of IFABP, or whether the chronic exposure to a HF challenge was needed to develop the blunt villus and other phenotypic changes observed in the IFABP\(^{-/-}\) mouse. Thus, a cohort of IFABP\(^{-/-}\) and WT mice were fed a 10% Kcal fat LF diet for 12 weeks beginning at 8 weeks of age. LF fed IFABP\(^{-/-}\) mice were found to have an average villus length that was 17% shorter than their WT counterparts (P<0.01) (Fig 3-11A), about half the decrease found under HF feeding (Fig 3-5). Unlike the HF fed mice, no reduction in muscularis thickness was observed in the IFABP\(^{-/-}\) compared to the WT group (Fig 3-11B). As expected for mice that have shorter villi, IFABP\(^{-/-}\) mice had less total goblet cells (P<0.05) (Fig 3-11C). However, when the amount of goblet cells was normalized to the average villus length, no difference in goblet cell density between groups was found (Fig 3-11D). In addition to histological assessments, total fecal output and intestinal transit time were determined for the LF fed IFABP\(^{-/-}\) and WT mice. Unlike their HF fed counterparts, no differences were observed in total fecal output or intestinal transit time (Fig 3-11EF).
Figure 3-11: Initial small intestinal phenotype assessments in 10% Kcal fat HF fed WT (●) and IFABP−/− (■) mice. A, Average villus length (n=3). B, Average muscularis thickness (n=3). C, Total villus goblet cells (n=3). D, Average goblet cell density (n=3). E, Assessment of total fecal excretion normalized to average food intake (n=5). F, Assessment of intestinal transit time (n=10-12).
**Discussion**

Proximal intestinal enterocytes express the FABPs, IFABP and LFABP. In humans, IFABP is less abundant than LFABP\cite{135,136}, however mice express similar levels of LFABP and IFABP within the small intestinal mucosa\cite{135–137}. While no compensatory upregulation of LFABP was observed in chow-fed IFABP null mouse intestine\cite{15}, we wondered whether a high fat diet might lead to increased LFABP expression. We found, however, that as with the chow fed mice, HF fed IFABP−/− mice did not have a compensatory increase in LFABP gene expression or protein abundance, and no change in the gene expression of the distal small intestinal FABP, ileal-FABP (ILBP; FABP6) was observed. Thus, the phenotypic changes observed in the IFABP−/− mice appear to be independent of the abundance of other FABPs, further supporting the independent and distinct roles of the proximal small intestine FABPs, IFABP and LFABP, in intestinal and whole-body homeostasis.

Notably, total fecal mass per gram of food intake of HF fed IFABP−/− mice was markedly greater than that of the WT mice. This increase in fecal output in the absence of changes in lipid concentration was unanticipated and suggested that intestinal transit time might be impacted by IFABP−/− deletion. Indeed, we found that the HF fed IFABP−/− mice had significantly more rapid intestinal transit, relative to WT mice. Thus, the enhanced intestinal transit and increased fecal excretion suggests that IFABP−/− mice are in fact malabsorbing nutrients in general, including lipid. Indeed, bomb calorimetric assessments revealed reduced energy absorption in HF fed IFABP−/− mice. It is therefore likely that the reduced absorption energy absorption coupled with decreased food intake, explains why the IFABP−/− mice remain lean on both HF and very HF diets. The alterations in total fecal output and intestinal transit time appear to be absent in LF fed IFABP−/− mice, suggesting that the ablation of IFABP in addition to a HF challenge are necessary for these physiological alterations to be observed. Ironically, these studies support the prevailing hypothesis that IFABP is involved in efficient dietary lipid assimilation, although the present results
indicate that the effects of IFABP ablation are not related to specific alterations in intestinal lipid processing.

It is interesting to note that the shorter villi may also contribute to the observed more rapid intestinal transit rates. Villus length decreases from the duodenum to the ileum, allowing for peristaltic contractions to more rapidly move intestinal contents as they descend \(^{223}\), while still allowing for the efficient absorption of dietary nutrients \(^{11}\). Shorter proximal intestinal villi in IFABP\(^{-/}\) mice small intestine would provide less resistance for passing luminal contents, allowing them to more rapidly traverse the GI tract. Additionally, the shorter villi may explain, in part, the leanness of HF fed IFABP\(^{-/}\) mice, with more rapid intestinal motility leaving less time and less surface area for efficient nutrient absorption.

It was found that the muscularis layer of the proximal small intestine is thinner in HF fed IFABP\(^{-/}\) mice, which may explain, in part, the above noted fragility of the SI. Additionally, the shorter average villus length of IFABP\(^{-/}\) mice suggests that there is less surface area for tight junction (TJ) and adherens junction (AJ) interactions. We initially hypothesized that the shorter villi might be a result of reduced crypt cell proliferation. However, mice injected with BrdU 2 hours prior to tissue collection revealed that both groups have comparable levels of BrdU positive cells in their crypts. Instead, it is likely that the blunt villus phenotype is due to enhanced cell death, since samples acquired from mice 48 hours after BrdU injection demonstrated that IFABP\(^{-/}\) mice had significantly less BrdU positive cells present in their villi, when compared to WT mice. It is possible that the IFABP\(^{-/}\) small intestinal cells are susceptible to ER stress induced apoptosis \(^{224}\). Some markers of ER stress, such as ATF6 and caspase 3 gene expression, were elevated in the mucosa of HF fed IFABP\(^{-/}\) mice. Additionally goblet cells and Paneth cells, hypersecretory cells present within the small intestine, are more sensitive to more deleterious effects of ER stress, and tend to have reduced abundance in response to chronic inflammation and ER stress \(^{224,225}\). Since IFABP\(^{-/}\) mice have reduced goblet cell density and Paneth cell abundance, it is possible
that these cells, along with other cell types in the small intestine, are dying via apoptosis, and inducing the blunt villus phenotype that is observed.

The vagus nerve (VN) plays a major role in the regulation of GI motility. Visceral afferent endings of the VN in the intestine express a diverse array of mechanosensitive and chemical receptors. These receptors bind gut peptide hormones that are released from enteroendocrine cells of the GI tract, responding to nutrients, distension of the stomach, and neuronal signals. Vagal afferent neurons also express cannabinoid receptor 1 (CB1R), which is part of the complex endocannabinoid system (ECS), a signaling system that is known to play a large role in the regulation of food intake. Interestingly, chemical inhibition of CB1R in rodents results in increased intestinal motility. Additionally, whole-body and VN-specific inhibition of CB1R both result in increased intestinal propulsion in mice. Taken together, CB1R-related signaling within the VN appears to play an important role in modulated GI motility. Several FABPs have been shown to bind ECs, and appear to be involved in the regulation of intracellular EC levels. Mice Interestingly, we showed that the IFABP−/− mice had somewhat lower mucosal levels of 2-arachidinoylglycerol (2-AG), an EC that acts as a full agonist of CB1R. Activation of CB1R by receptor agonists has been shown to decrease intestinal motility in rodent models, while antagonism leads to more rapid intestinal transit. Thus, in HF fed IFABP−/− mice the observed increase in intestinal motility may be secondary to altered vagal tone caused by reduced CB1R activation, as a result of lower mucosal EC levels.

Overall, the shorter length of the IFABP−/− mucosal villi would appear to have important implications for intestinal transit, nutrient absorption, and intestinal integrity. Others have reported that the villus length of IFABP−/− mice maintained on a low fat chow diet did not differ from that of their WT counterparts, while we found a small but significant decrease, relative to WT, on a semi-purified 10% kcal LF diet, and a large decrease in villus length on the 45% kcal HF diet. It is likely that dietary fat amount and type play an important role in these differences. Over the past few years,
it has become evident that diets rich in lipids, especially saturated fats, lead to alterations in intestinal structure and physiology. Thus, the IFABP−/− mice may be more sensitive to the effects of lipid-rich diets, leading to more drastic alterations in villus morphology in response to HFDs. The differences in the observed villus length phenotypes in response to different diets could also be due to alterations in the composition of the gut microbiota, which play a role in shaping, and are shaped by, the environment within the intestinal lumen. It has been demonstrated that HF feeding can induce intestinal dysbiosis, leading to pathophysiological changes that include chronic low-grade inflammation, impaired mucus production, and altered expression of tight junction proteins. In relation to potential alterations in the microbiome, differences in the villus length phenotypes of the chow fed IFABP−/− mice compared to our LF fed and HF fed IFABP−/− mice may also be due to the fact that semi-purified diets used differs from standard chow diets in fiber quality as well. Many LF and HF semi-purified diets use cellulose, and insoluble fiber, as the sole source of dietary fiber. However, standard chow also contains soluble fiber, which is able to be processed by the microbiome to provide energy for the microbes that are present. The lack of soluble fiber in the semi-purified diets subsequently “starves” the microbes that are present within the GI tract, which can drastically alter the structure and composition of the microbiome. The lack of soluble fiber appears to influence the morphology and structure of the GI tract as well, with chronic intake of diets that lack soluble fiber leading to reduced colon length, colon weight, and cecum weight. Interestingly, the addition of inulin, a soluble fiber, to a semi-purified HF diet rescues the mice from the physiological alterations that are observed with diets that lack soluble fiber, with HF fed inulin supplemented mice having colon length, colon weight, and cecum weights similar to that of chow fed mice. Thus, it is possible that the previously reported absence of changes observed in the intestinal morphology of chow fed IFABP−/− mice, relative to the present changes observed in the intestinal morphology of IFABP−/− mice fed semi-purified LF and HF diets, may also be due to difference in soluble fiber content.
It has been reported that HF fed obese mice have elevated levels of plasma endotoxin, a bacterial component that passes from the intestinal lumen into the circulation when there is increased intestinal permeability. Interestingly, we found that although the 45% Kcal HF fed IFABP−/− are leaner than their WT counterparts, they have similar levels of plasma endotoxin. In fact, both the IFABP−/− mice and WT mice have plasma endotoxin levels that are similar to those that have been observed in mouse models of diet induced obesity, suggesting that the IFABP−/− mice, though lean, may experience increased intestinal permeability in response to chronic HF feeding.

As a more direct assessment of intestinal permeability, FITC-dextran assays were performed, revealing that IFABP−/− mice have increased intestinal permeability. Together with the alterations found in TJ-related gene expression levels, increased permeability likely explains the initially observed intestinal fragility phenotype of the IFABP−/− mouse.

Among the TJ proteins of the GI tract, claudins constitute the major transmembrane component. Claudins act as “gatekeepers”, and can be classified as either barrier-forming or channel-forming. Different claudins polymerize to form mesh-like structures in which the integrity is influenced by the balance of barrier-forming and channel-forming claudins. An imbalance of either group can lead to dysfunctional tissue that is more prone to structural damage and inflammation. In the IFABP−/− mucosa, we found increased expression of the channel-forming claudin 2 and decreased expression of the barrier-forming claudin, claudin 5. These same directional changes were observed with IHC staining, with IFABP−/− mice having increased claudin 2 staining and decreased claudin 5 staining. These changes are associated with a “leaky gut” phenotype, which may partly explain why the IFABP−/− mice have increased intestinal permeability. Interestingly, this pattern of gene expression has been observed in samples obtained from patients with Crohn’s disease, an inflammatory bowel disease in which the integrity of the small intestine is compromised. Indeed, there is evidence that FABPs present in the small intestine change their expression pattern in celiac disease, another GI-related disease that involves chronic
inflammation and in which damaged villi cause a variety of symptoms, some of which are related to nutrient malabsorption. In intestinal mucosa from celiac disease patients, both IFABP and LFABP appear to be expressed not only in cells of the remnant epithelium but also within the hyperproliferative crypts, where FABPs are typically not expressed. It is possible that abnormal FABP expression, such as a lack of IFABP expression or induced expression of FABPs in the crypts, may be a common phenotype of GI-related disorders that include altered intestinal morphology, structure, and the overall "leaky gut" phenomenon.

It should be noted that dysbiosis-induced inflammation may not easily occur in mice that have more rapid intestinal transit. Early studies in which intestinal motor activity was assessed in the context of small intestinal bacterial clearance demonstrated that the action of peristalsis is the primary line of defense against abnormal bacterial colonization of the small intestine. Thus, it is possible that the rapid intestinal transit time of the IFABP−/− mice may be a compensatory response to the alterations occurring in their SI structure and morphology that would normally make them more susceptible to the induction of inflammation.

In addition to the array of junctional and junction-related proteins that directly or indirectly alter the permeability of the intestinal epithelium, secretory goblet cells along the GI tract secrete mucus that acts as an initial defensive barrier, providing protection from physical and chemical challenges. The mucus layer can be divided into two functional components: the top layer, or loosely adherent layer, which is able to trap bacteria and prevent them from interacting with the epithelium, and the bottom layer, or firmly adherent layer, which provides structural support and provides a critical barrier for preventing bacterial adhesion to the epithelium. Interestingly, deficiency of the primary component of the GI mucus layer, the glycoprotein mucin 2 (MUC2), leads to the elimination of the mucus layer, increased intestinal permeability, and increased bacterial adhesion to the epithelial surface. It is worth noting that goblet cells are also able to secret trefoil factors (TFFs), which play important roles in the maturation and
maintenance of many small intestinal components \(^37,38\). Additionally, it has been demonstrated that chronic inflammation of the GI tract can result in depletion of goblet cells, leading to alterations of the not only the mucus layer, but intestinal morphology and structure as well \(^37,38,41\). The reduced goblet cell density of the HF fed IFABP\(^{-/-}\) mucosa implies that there is a reduced or altered mucus layer, which in turn may contribute to the fragility of IFABP\(^{-/-}\) mice small intestine. Interestingly, while HF fed IFABP\(^{-/-}\) mice had both a reduction in total goblet cells and villus length-independent goblet cell density, LF fed IFABP\(^{-/-}\) mice only displayed a villus length-dependent reduction in total goblet cell, suggesting that the HF challenge in addition to the ablation of IFABP is necessary to induce villus-length independent alterations in goblet cell density.

It should be noted that while reductions of both goblet cell number and mucin 2 protein levels were observed in the small intestine of HF fed IFABP\(^{-/-}\) mice, mucosal mucin 2 and mucin 3 gene expression did not differ between IFABP\(^{-/-}\) mice and WT mice. It is known that highly secretory cells, such as goblet cells, are very sensitive to the deleterious effects of chronic ER stress \(^224,225\). Additionally, iNOS, COX2, and MCP1 are known to be markers of ER stress, with increased expression and abundance being observed in chronic ER stress responses \(^243–251\). Thus, the maintenance of mucin 2 and mucin 3 gene expression in conjunction with decreased goblet cell density, reduced mucin 2 staining, and increased iNOS, COX2, and MCP1 staining in the small intestine of IFABP\(^{-/-}\) mice suggests that ER stress may play a role in the development of the HF fed IFABP\(^{-/-}\) intestinal phenotypes. The upregulated expression of ATF6 and Caspase 3, both of which are markers of ER stress and apoptosis \(^224,225\) supports this suggestion. Additionally, reduced Paneth cells were also found in the small intestine of HF fed IFABP\(^{-/-}\) mice; these hypersecretory cells, which secrete an array of antimicrobial peptides are known to be particularly sensitive to ER stress \(^44,224\). Despite these observed alterations it is important to note that the expression of CCAAT-enhancer-binding protein homologous protein (Chop) and spliced X-box-binding protein1 (Xbp1s), which are also markers of ER stress, were not elevated in the IFABP\(^{-/-}\).
mucosa. Additionally, enhanced phosphorylated eIF2α, which is a well-accepted marker of ER stress induction\textsuperscript{224,225}, was also not observed suggesting that if ER stress is playing a role in the phenotypes observed in the IFABP\textsuperscript{-/-} mice, it is likely not a major role. However, it is important to mention that the mice assessed in these studies were all fasted for 16 hours prior to tissue collection, unless stated otherwise. ER stress is known to be influenced by circadian cycling\textsuperscript{252–254}, so it is possible that more robust ER stress-related phenotypes in IFABP\textsuperscript{-/-} mice may be observed at different ages or in response to different fasting challenges.

It is possible that the ablation of IFABP may make the intestinal epithelial cells more susceptible to FA-induced lipotoxicity, which could subsequently promote ER stress. Interestingly, some of the phenotypes that are observed in HF IFABP\textsuperscript{-/-} mice have also been observed in mice with an intestine-specific ablation of X-box-binding protein1 (XBP1). XBP1 is a transcription factor that is essential to the unfolded protein response (UPR) that is a hallmark of the physiological attempt to resolve ER stress\textsuperscript{255}. Intestine-specific XBP1\textsuperscript{-/-} mice were found to have almost no Paneth cells, and a reduction in goblet cell abundance\textsuperscript{255}. As mentioned above, since IFABP\textsuperscript{-/-} mice do not appear to have reduced crypt cell proliferation, it is tempting to speculate that the blunt villus phenotype and alterations in goblet cell and Paneth cell populations might be due, instead, to enhanced apoptosis that may occur via the ER stress response. Indeed, IFABP\textsuperscript{-/-} mice that were exposed to BrdU 48 hours prior to tissue collection appear to have enhanced cell death; this apparent enhancement of cell death may be due to ER stress-related apoptosis, ER stress-independent apoptosis, or anoikis (cell shedding)\textsuperscript{256,257}.

The present results indicate that IFABP is not specifically essential for dietary lipid assimilation. Rather, it appears to be functioning, perhaps via EC or FA binding, to regulate intracellular signaling and/or transcriptional programming. Indeed, some members of the FABP family have been shown to interact with nuclear hormone receptors (NHRs) such as peroxisome-proliferator activated receptors (PPARs) and hepatocyte nuclear factors (HNFs)\textsuperscript{113,155,158,258}. Taken together
the changes observed in IFABP+/− mouse proximal small intestinal morphology, structural genes, markers of ER stress, Paneth cell abundance, and goblet cell density are likely indicative of reduced structural integrity. Thus, these studies suggest that IFABP likely plays a role in dietary lipid sensing and signaling, modulating intestinal structure and capacity for nutrient absorption, thereby subsequently altering whole-body energy metabolism.
Chapter 4

General Conclusions and Future Directions
The Ablation of Intestinal LFABP Does Not Fully Recapitulate the MHO Phenotype of the whole body LFABP null mouse

Obesity is a multifaceted disease that is characterized by excessive fat storage that is often accompanied by metabolic dysfunction. A subset of the obese population appears metabolically healthy despite their obesity (MHO), not displaying various comorbidities that are common. Although male HF fed LFABP-/- mice become more obese they remain relatively healthy, being normoglycemic, normoinsulinemic, and retain exercise endurance similar to that of leaner mice. Here, we have shown that the intestine-specific ablation of LFABP does not result in male mice that are more obese. However, in response to a chronic HF challenge LFABPint-/- mice still had an exercise capacity that was similar to that of a healthy LF fed animal. Female LFABPint-/- did appear more akin to an MHO model, displaying both obesity and a retained exercise capacity, normal fasting insulin, and normal glucose tolerance when compared to their leaner LFABPfl/fl controls. However, other health parameters, such as hepatic TG content and serum lipids in, should be assessed in both male and female LFABP-cKO mice to continue a determination of relative health. Additionally, HF fed female whole-body LFABP-/- mice should also be assessed to determine if they display a MHO set of phenotypes as well. Others have assessed HF fed female LFABP-/- mice, with one group finding that they were resistant to diet-induced obesity, while another group demonstrated that female LFABP-/- gained more weight when challenged with a HF diet. It should be noted that the male mice assessed by these groups also followed a similar pattern, with one group observing resistance to diet induced obesity in their male LFABP-/- mice, while the other group (and our group) saw increased adiposity. The underlying reasons for different phenotypes may include strain background, gene ablation strategies, and different diet compositions used, as previously discussed. It is also possible that differences and similarities observed between our LFABP-/- mice and the Texas mice, compared to the LFABP-/- mice used by the St. Louis group is due to differences in microbiomes.
between the groups. Ongoing studies are occurring to assess the microbiomes of the enterocyte FABP null mice, to determine what bacteria or bacterial products may influence the whole-body phenotypic changes that have been observed in both LFABP<sup>-/-</sup> and IFABP<sup>-/-</sup> mice.

While we have not yet assessed how the whole-body female LFABP<sup>-/-</sup> mice respond to the HF feeding protocol in our hands, it is likely that they would be prone to increased adiposity. Indeed, similar to the observed increased BW gain and fat mass in female LFABP<sup>int/-</sup> mice, female LFABP<sup>Liv/-</sup> mice also appear to become more obese in response to chronic HF feeding (unpublished observations). It is likely that female LFABP<sup>-/-</sup> mice will retain, or have an exacerbated, obese phenotype.

These current studies using the IFABP<sup>-/-</sup> mice have demonstrated that alterations in intestinal morphology and structure can have dramatic influences on whole-body physiological responses. Future studies assessing aspects of the MHO phenotype in LFABP-cKO mice should also include assessments of intestinal physiology. Recently, we have found that male HF fed LFABP<sup>-/-</sup> mice display a reduction in fecal output that can be partly explained by having a longer intestinal transit time (unpublished data), a phenotype that is opposite of what is found in the leaner HF fed IFABP<sup>-/-</sup> mice. The reduction in fecal output, in addition to increased food intake<sup>16</sup>, may, at least in part, explain the obese phenotype that is observed in the HF fed LFABP<sup>-/-</sup> mice. In addition to alterations in intestinal transit, histological examination of HF fed LFABP<sup>-/-</sup> mice small intestine revealed no differences in average villus length, but a significant reduction in goblet cell density (unpublished data). Whether these transit and morphology phenotypes are present in female LFABP<sup>-/-</sup> or male and female LFABP<sup>int/-</sup> mice remains to be determined. Overall, it is apparent that the ablation of LFABP specifically in the intestine is able to influence aspects of whole-body physiology. Additionally, sex-related differences observed between the male and female LFABP<sup>int/-</sup> responses to chronic HF feeding, suggests an important role for gender as well.
Alterations Specific to the Intestine Can Induce Dramatic Whole-Body Responses

It is interesting that LFABP−/− and LFABPint−/− mice are able to retain their exercise capacity in response to chronic HF feeding, being able to run for a longer time during an induced exercise challenge, whereas HF-fed WT mice show a significant decline in exercise capacity. Since LFABPint−/− mice and LFABPfl/fl mice had similar values for spontaneous activity, the retained exercise capacity in the LFABPint−/− mice seems to be independent of changes in spontaneous activity, and suggest that there may be crosstalk occurring between the intestine, skeletal muscle, and perhaps cardiac muscle. Indeed, other studies have demonstrated that exercise induces signals that allow for intestine/muscle communication, and it appears that these signals are mediated by the microbiome and mitochondria. Recent studies have demonstrated that short chain fatty acids and secondary bile acids produced by commensal gut microbiota might influence mitochondrial functions related to mitochondrial biogenesis, energy production, redox balance, and inflammation. For example, commensal gut bacteria are able to reduce reactive oxygen species (ROS) production via SCFA induced signaling, which can protect mitochondria from the presence of excessive ROS that occur in response to endurance exercise training. Future studies should focus on elucidating the mechanism by which intestinal ablation of LFABP is able to influence responses to endurance training bouts. These studies should include a detailed analysis of the microbiome, and the metabolites that might be generated that can influence intestinal, skeletal muscle, and cardiac muscle responses to endurance exercise. It also may be of interest to observe if LFABP−/− or LFABPint−/− mice respond better to chronic endurance training when compared to WT controls.

The ablation of IFABP, a protein that is only expressed in the intestine, also appears to have great influence over whole-body phenotypic responses. Most notable, of course, is the lean phenotype that is observed in response to chronic HF feeding. It is apparent that this phenotype is, at least partly, influenced by intestinal physiology, having an etiology that appears to be linked to
alterations in morphology and peristaltic contractile movement. The blunt villus phenotype has implications relating to nutrient absorption, intestinal transit, and structural stability. Additionally, the reductions observed in specific cell populations, such as Paneth cells and goblet cells, in addition to the observed increase in villus cell death, suggest an integral role for IFABP in the maintenance of a normal, functional small intestinal epithelium. It is especially important to note that these changes appear to be, at least partially, independent of dietary fat content, since the morphological phenotypes are present, albeit to a lesser extent, in the LF fed as well as the HF fed IFABP−/− mice.

An important question that remains to be answered is, how does the ablation of IFABP result in more rapid intestinal transit in HF fed animals? The more rapid transit might be influenced by the blunt villus phenotype, since there would be less surface area to provide resistance for passing intestinal contents. However, LF fed IFABP−/− mice also displayed a blunt villus phenotype without having significant alterations in intestinal transit time. Instead, it is possible that the ablation of IFABP in conjunction with chronic HF feeding results in altered gut/brain communication. There is substantial evidence that the gut/brain axis plays a role in regulating movement of foodstuffs throughout the GI tract. We have observed that HF fed IFABP−/− mice appear to have altered mucosal levels of endocannabinoids (EC) and EC-like molecules, which are thought to play a role in how the gut and brain communicate. It is also possible that the ablation of IFABP may influence cell populations in addition to Paneth cells and goblet cells. Enteroendocrine cells, such as K cells or L cells, secrete hormones that are able to modulate appetite and intestinal motility. For example, gastric inhibitory polypeptide (GIP) has traditionally been thought to be involved in reducing GI motility, though more recent studies have revealed that the primary role of GIP is to induce insulin secretion from pancreatic beta cells. Another peptide hormone, motilin, has been shown to induce GI movement, and its secretion is reduced in response to elevated insulin signaling. Historically, the dogma involving enteroendocrine
cells and the hormones that they secrete is that each cell type secretes a specialized hormone (see Chapter 1, Fig 1-3B). However, more recent studies have revealed that each type of enteroendocrine cell is able to secrete an array of hormone peptides, and that the types of peptides that are secreted is likely influenced more so by the location of the cells in the GI tract. It is thought that the relative balance of secreted hormones, termed the “secretome”, determines the messages that the GI tract sends to other organs. Since the intestine of IFABP−/− mice has alterations in other cell populations, and they appear to have enhanced cell death, it is possible that the relative abundance of various enteroendocrine cell types might also be affected, which would in turn, altered the intestinal secretome. Alterations in the intestinal secretome would have important implications relating to gut/brain communication. For example afferent endings of the vagus nerve (VN) in the intestine express an array of mechanosensitive and chemical receptors. The chemical receptors are able to bind gut peptide hormones that are released from enteroendocrine cells of the GI tract. In addition to having receptors for gut peptide hormones, VN afferents also express the EC receptor, cannabinoid 1 receptor (CB1R). Chemical inhibition and genetic silencing of CB1R in rodent models results in increased GI motility. Moreover, VN-specific ablation of CB1R also results in increased GI motility, suggesting that ECS signaling in the VN plays an important role in regulating motility. It is possible that the trend toward lower EC and EC-like molecules observed in the mucosa of IFABP−/− mice may lead to reduced EC stimulation of VN CB1R, which in turn, could result in more rapid GI motility. Future studies should assess the potential crosstalk occurring between the small intestine and various regions of the brain and central nervous system. A detailed analysis of the EC system in both tissues may help elucidate the mechanisms that may regulated alterations in intestinal transit in the HF fed IFABP−/− mice. The analysis of intestine/brain crosstalk should also include plasma and tissue levels of enteroendocrine cell peptide hormones, such as GIP and motilin. Additionally, it will be important to analyze mice that have not been fasted, in addition to
the fasted mice, since the regulation of EC and enteroendocrine peptide levels are influenced by fasting/feeding challenges.115,121

**The Ablation of IFABP Induces an Intestinal Fragility Phenotype**

It was observed during tissue collection that HF fed IFABP\(^{-/-}\) mice have small intestines that appear to be more fragile relative to their WT counterparts. Here, we have demonstrated that HF fed IFABP\(^{-/-}\) mice have a blunt villus phenotype, a thinner muscularis layer, reduced goblet cell and Paneth cell densities, and increased intestinal permeability. Some, but not all, of these phenotypes appear to be present in the LF fed IFABP\(^{-/-}\) mice. For example, while the LF fed IFABP\(^{-/-}\) mice do display the blunt villus phenotype, they do not have a thinner muscularis layer. Future studies will focus on the mechanism of how the ablation of IFABP induces intestinal fragility. As mentioned above, members of the FABP family have been proposed to act as lipid chaperones, being able to influence lipid related signaling through the transport of, or sequestration of, lipid ligands.130,267,268 We have recently shown that IFABP\(^{-/-}\) mice have altered gene expression for several transcription factors, including HNF4α, RXRα, RARβ, and SREBP1 (see Appendix). Some of these transcription factors, such as HNF4α, are known to influence cell growth, development, and death.158,159,269 Thus, it is possible that the ablation of IFABP alters the intestinal transcriptome in a way that either reduces cell differentiation, which would explain the reduced populations of goblet and Paneth cells, and/or in a way that increases the rate of cell death, which would explain both the blunt villus and altered cell population phenotypes. Future studies should assess transcriptional targets of the transcription factors in which altered expression was observed. Additionally, those transcription factors should also have their relative protein abundance determined, to determine if changes in gene expression correlate with similar changes in protein abundance.
The Gastrointestinal Tract Plays a Large Role in Whole-body Responses to Nutrient Challenges

While the integral role the GI tract plays in efficient nutrient absorption and assimilation has been appreciated for many years, it is evident that alterations induced in or related to this organ system can have drastic impacts on whole-body physiological responses. This work has demonstrated a role for enterocyte lipid binding proteins in efficient uptake and trafficking of not only dietary lipid, but nutrients in general. These studies have also revealed a heretofore unappreciated role for the enterocyte FABPs in modulating intestinal physiology, intestinal morphology, and whole-body ramifications of such modulations. These studies also reaffirm the importance of assessing the potential for tissue-tissue crosstalk to be occurring in response to various stimuli. While studies that assess gut-brain communication are relatively common, there is a notable gap in the literature relating to studies that assess cross talk between gut and muscle. For future studies, in order to assess how the intestine is able to influence whole-body phenotypic responses, it will be important to specifically focus on the bi-directional communication that can occur between various organs and organ systems.
Appendix

Ablation of IFABP Reduces CRBP2 Expression without altering CRBP2 Abundance, Modulates Mucosal Expression of Vitamin A Related Genes, and Alters Whole-Body Retinoid Status
Abstract

Intestinal-fatty acid binding protein (IFABP; FABP2) is a 15 kDa intracellular protein abundantly present in the cytosol of the small intestinal enterocyte. High fat (HF) feeding of IFABP<sup>−/−</sup> mice resulted in reduced weight gain and fat mass relative to wild-type (WT) mice. IFABP<sup>−/−</sup> mice were also found to have alterations in intestinal morphology and structure. We have previously demonstrated that the ablation of IFABP does not result in compensatory upregulation of liver-FABP (LFABP; FABP1), another highly expressed intestinal FABP. Another member of the FABP gene family, Cellular retinol binding protein 2 (CRBP2), is also expressed in small intestine. In this study we assessed the level of CRBP2 gene expression and protein abundance in IFABP<sup>−/−</sup> mice. We found a drastic reduction in mucosal CRBP2 message in IFABP<sup>−/−</sup> mice. Nevertheless, CRBP2 protein levels were comparable to that of WT mice, suggesting that CRBP2 mRNA stability and/or protein stability was altered in response to the ablation of IFABP. Additionally, both low fat (LF) and HF fed IFABP<sup>−/−</sup> mice were found to have altered mucosal expression of vitamin A-related genes, and altered retinoid levels in liver and plasma.
Introduction

The fatty acid binding protein (FABP) family is a class of small (14-15 KDa) cytosolic proteins that are able to bind an array of hydrophobic molecules with high affinity. The family consists of 9 FABPs, with additional cellular retinol binding proteins (CRBPs) also comprising part of the family. It is thought that these proteins are necessary for the efficient intracellular transport of various hydrophobic ligands, and that they may play a role in preventing fatty acid (FA) induced cytotoxicity. Given that the small intestine is responsible for the uptake and assimilation of the large amount of dietary FA, it has been hypothesized that the enterocyte FABPs are necessary for efficient trafficking of dietary lipids \(^{11,12}\).

Indeed, the small intestine expresses at least 4 different members of the FABP family, with three of these members being very highly expressed throughout the length of the tissue. Liver-FABP (LFABP or FABP1) is highly expressed in both the intestine and liver \(^{11}\). LFABP is an atypical member of the FABP family, having 2 ligand binding domains and transferring ligands with a diffusional transfer mechanism \(^{146,147}\). Intestinal-FABP (IFABP or FABP2) is only found in the small intestine \(^{11}\) and is more representative of the typical ligand interactions that are observed with the FABP family, having only one binding domain and transferring ligands with a collisional transfer mechanism \(^{146,147}\). In addition to LFABP and IFABP, the small intestine also has high expression of CRBP2 \(^{127,138}\). Unlike LFABP and IFABP, which have high affinities for FAs, CRBP2 has a high affinity for retinol, and has been hypothesized to be necessary for the efficient uptake of dietary retinol. More recently, we have shown that CRBP2 is also able to bind 2-monoacylglycerols (2-MGs), such as the endocannabinoid (EC) 2-arachidonoyl glycerol (2-AG) (Lee et al., 2019 Submitted). The last small intestinal FABP that is expressed in the small intestine is the ileal bile acid binding protein (ILBP or FABP6) \(^{11}\). While LFABP, IFABP, and CRBP2 are found throughout the small intestine, with the highest expression of each being observed in the more proximal
region when compared to the more distal region, ILBP is expressed mainly in ileum, where it is thought to play a role in bile acid metabolism.\textsuperscript{11,138,270,271}

Previous \textit{in vitro} and \textit{ex vivo} studies suggested that LFABP and IFABP may be necessary for the efficient absorption of dietary FAs.\textsuperscript{148,184} Since LFABP and IFABP are similar in structure and they bind similar ligands, it was hypothesized that the ablation of one FABP may lead to increased expression of the other FABP, compensating for the loss of a highly expressed protein. Previously, we have shown that the ablation of LFABP in chow mice did not cause compensatory upregulation of IFABP mRNA or protein; the ablation of IFABP did not result in upregulation of LFABP as well.\textsuperscript{15} More recently we have demonstrated that mice challenged with a 45\% Kcal fat high fat (HF) diet also do not appear to have compensatory upregulation of other FABPs (see Chapter 3). In that set of experiments, in addition to LFABP and IFABP, the gene expression of ILBP and other FABPs that are not typically expressed in the small intestine were assessed. However, the expression of CRBP2, the other major intestinal FABP, has not previously been analyzed. Therefore, in the present studies, we assessed intestinal mucosal expression of CRBP2 and other vitamin A related genes in low fat (LF) and HF fed wild-type and IFABP\textsuperscript{−/−} mice. Additionally, intestinal mucosal, liver, and plasma retinoid levels were measured to obtain a general assessment of vitamin A status.

\textbf{Experimental Procedures}

\textbf{Animals and Diets}

As previously reported, the IFABP\textsuperscript{−/−} mice used in this study are a substrain bred by intercrossing of an original strain of IFABP\textsuperscript{−/−} mice and are congenic on a C57BL/6J background.\textsuperscript{15,128,191} C57BL/6J mice from The Jackson Laboratory (Bar Harbor, ME) were bred as wild-type (WT) controls. Mice were housed 2-3 per cage unless specified otherwise, maintained on a 12-hour light/dark cycle, and allowed \textit{ad libitum} access to standard rodent chow (Purina Laboratory
Rodent Diet 5015). At 2 months of age, male WT and IFABP\(^{-/-}\) mice were fed either a 45% Kcal fat high fat diet (HFD) (D10080402; Research Diets, Inc., New Brunswick, NJ), or a matched 10% Kcal LFD (D04051701; Research Diets) as indicated. The vitamin A content for both diets was 4IU/g. Body weights (BW) were measured weekly for a period of 12 weeks.

**Preparation of Tissue and Plasma**

Mice were fasted for 16 hours prior to sacrifice unless otherwise stated. At sacrifice blood was drawn; plasma was isolated after centrifugation for 6 minutes at 4000 rpm, and stored at -80°C. Livers were removed, immediately placed on dry ice, and stored at -80°C for further analysis. The small intestine from the pyloric sphincter to the ileocecal valve was removed, measured lengthwise, rinsed with 60mL of ice-cold 0.1M NaCl, and opened longitudinally. Intestinal mucosa was scraped with a glass microscope slide into tared tubes on dry ice and stored for future use.

**RNA Extraction and Real-Time PCR**

Total mRNA was extracted from small intestinal mucosa and analyzed as previously described\(^{15,16}\). Primer sequences were obtained from Primer Bank (Harvard Medical School QPCR Primer Database) and are shown in Table 1. The efficiency of PCR amplifications was analyzed for all primers to confirm similar amplification efficiency. Real time PCRs were performed in triplicate using an Applied Biosystems 7300 instrument. Each reaction contained 80ng of cDNA, 250nM of each primer, and 12.5μL of SYBR Green Master Mix (Applied Biosystems, Foster City, CA) in a total volume of 25μL. Relative quantification of mRNA expression was calculated using the comparative Ct method, normalized to TATA-binding protein (TBP).

**Western blotting**

Small intestinal mucosa was harvested as described above, and homogenized in 10x volume of PBS pH 7.4 with 0.5% (vol/vol) protease inhibitors (Sigma 8340) on ice with a Potter Elvejhem homogenizer. Total cytosolic fractions were obtained by ultracentrifugation (100,000g, 1 hour at
4°C) and protein concentration determined by Bradford assay. Thirty micrograms of cytosolic protein for each sample were loaded onto 15% polyacrylamide gels and separated by SDS-PAGE. The proteins were transferred onto 0.45μm nitrocellulose membranes using a semidy transfer system (Bio-Rad) for 1 hour and 45 minutes at 23 V. Prior to blocking, total protein was visualized with Ponceau staining. Membranes were blocked by incubating in 5% nonfat dry milk overnight at 4°C, and were incubated with the primary antibody, α-CRBP2 (1:10000, for 1 hour at room temperature; Abcam ab180494). After thorough washing, blots were incubated in α-rabbit IgG-horseradish peroxidase conjugate (1: 20,000) for 1 hour, and developed by chemiluminescence (WesternBright Quantum, Advansta, Menlo Park, CA). Protein expression was quantified by densitometric analysis with LI-COR Image Studio (Lite version 5.2). Target protein content was normalized to total protein content within a sample.

**HPLC Analysis of Tissue and Plasma Retinoids**

Reverse-phase HPLC analysis of retinol and retinyl ester was performed as described by Kim et al. In short, tissues were homogenized in 10 volumes of phosphate-buffered saline using a PRO200 homogenizer (Oxford, CT). Retinoids present in the homogenates were extracted into hexane and separated on a 4.6 × 250 mm Ultrasphere C18 column (Beckman, Fullerton, CA) preceded by a C18 guard column (Supelco Inc., Bellefonte, PA), with 70% acetonitrile, 15% methanol, and 15% methylene chloride used as the running solvent flowing at 1.8 ml/min. Retinol and retinyl esters (retinyl palmitate, oleate, linoleate, and stearate) were separated and identified by comparing retention times and spectral data of experimental compounds with those of authentic standards. Concentrations of retinol and retinyl esters in the tissues were quantified by comparing peak integrated areas for unknowns against those of known amounts of purified standards. Loss during extraction was accounted for by adjusting for the recovery of retinyl acetate, the internal standard added immediately following homogenization of the tissues.
Statistical Analysis

All group data are shown as average ± SEM. Statistical comparisons were determined between genotypes on the same diet using a two-sided Student’s t-test. Differences were considered significant for P<0.05.

Results

Mice lacking IFABP have drastically reduced expression of CRBP2 mRNA

The expression of CRBP2 mRNA in the intestinal mucosa was assessed in IFABP⁻/⁻ mice after 12 weeks of HF feeding. It was found that IFABP⁻/⁻ mice have dramatically reduced expression of CRBP2, with expression being 95% lower than that of WT mice (Fig 1). Subsequent analysis of other vitamin A-related gene expression revealed that IFABP⁻/⁻ mice have significantly increased expression of lecithin retinol acyl transferase (LRAT), retinoid X receptor alpha (RXRα), and sterol regulatory element binding protein 1 (SREBP1) (Fig 1). Additionally, IFABP⁻/⁻ mice have reduced expression of hepatocyte nuclear factor 4 alpha (HNF4α) and retinoic acid receptor beta (RARβ) (Fig 1). Similar to the dramatic reduction in CRBP2 expression, the expression of RARβ was 74% lower than that of WT mice (Fig 1).
Figure 1: Relative quantitation of small intestine mucosal mRNA expression of CRBP2 and other vitamin A-related genes in 45% Kcal fat HF fed WT (●) and IFABP−/− (■) mice. (n=8).
**IFABP−/− mice have normal CRBP2 protein abundance**

With there being such a dramatic reduction in CRBP2 mRNA observed in the IFABP−/− mice, it was anticipated that CRBP2 protein abundance would be lower as well. Western blotting was used to assess intestinal mucosal abundance of CRBP2 protein. Surprisingly, IFABP−/− mice have similar protein abundance of CRBP2, when compared to their WT counterparts (Fig 2). Liver samples were used as a negative control, since CRBP2 is only expressed in the small intestine of adult animals. As expected, a band for CRBP2 was only present for small intestinal mucosal samples.
Figure 2: Relative abundance of CRBP2 protein in 45% Kcal fat HF fed WT (●) and IFABP\(-/-\) (■) mice. (n=6).
**LF fed and HF fed IFABP$^{-/-}$ mice have alteration in tissue retinoid levels**

Plasma and tissue levels of retinol and retinyl ester was assessed in both LF and HF fed mice using HPLC. No changes were observed in small intestinal mucosal samples for both LF and HF fed mice (Fig 3). In the liver, while no changes were observed with LF fed mice, HF fed IFABP$^{-/-}$ mice were found to have lower retinol, and higher retinyl ester levels (Fig 3). The only significant change observed in the LF fed mice was a reduction in plasma retinol in the IFABP$^{-/-}$ mice (Fig 3).
Figure 3: Tissue and plasma retinol and retinyl ester levels in 10% Kcal LF fed and 45% Kcal fat HF fed WT (●) and IFABP<sup>+</sup> (■) mice. (n=6-10).
**LF fed IFABP<sup>−/−</sup> mice also have alterations in vitamin A-related gene expression**

The expression of vitamin A-related genes were also assessed in LF fed IFABP<sup>−/−</sup> and WT mice. Like their HF fed counterparts, IFABP<sup>−/−</sup> mice also displayed a drastic reduction in CRBP2 gene expression relative to WT mice (Fig 4). IFABP<sup>−/−</sup> mice also had reduced expression of SREBP1, peroxisome proliferator activated receptor alpha (PPARα), and LRAT, with a 52% reduction in LRAT being noted (Fig 4). Aside from the change in CRBP2, none of the other changes observed in the LF fed animals were also seen in the HF fed animals, and none of the changes observed in HF fed animals occurred in LF fed animals (Table 1).
Figure 4: Relative quantitation of small intestine mucosa mRNA expression of CRBP2 and other vitamin A-related genes in 10% Kcal fat LF fed WT (●) and IFABP−/− (■) mice. (n=6-8).
Table 1: Summary of gene expression analyses in LF and HF-fed small intestinal mucosa.

No difference (≈). Not analyzed (NA).

<table>
<thead>
<tr>
<th>45% Kcal HFD</th>
<th>10% Kcal LFD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gene</strong></td>
<td><strong>IFABP-/- (expression relative to WT)</strong></td>
</tr>
<tr>
<td>CRBP2</td>
<td>↓↓</td>
</tr>
<tr>
<td>LRAT</td>
<td>↑</td>
</tr>
<tr>
<td>DGAT1</td>
<td>≈</td>
</tr>
<tr>
<td>RXRα</td>
<td>↑</td>
</tr>
<tr>
<td>SREBP1</td>
<td>↑</td>
</tr>
<tr>
<td>HNF1α</td>
<td>≈</td>
</tr>
<tr>
<td>HNF4α</td>
<td>↓</td>
</tr>
<tr>
<td>HNF4γ</td>
<td>≈</td>
</tr>
<tr>
<td>PPARα</td>
<td>≈</td>
</tr>
<tr>
<td>PPARβ/δ</td>
<td>≈</td>
</tr>
<tr>
<td>PPARγ</td>
<td>≈</td>
</tr>
<tr>
<td>RARα</td>
<td>≈</td>
</tr>
<tr>
<td>RARβ</td>
<td>↓↓</td>
</tr>
</tbody>
</table>
Discussion

Vitamin A, a fat soluble micronutrient, is essential to many tissues for normal cell growth and differentiation \(^{138,273}\). It is found in animal-based foods in the form of retinyl esters, and in plant-based foods in the form of provitamin A carotenoids \(^{138,274}\). Prior to absorption, dietary retinol is cleaved by retinol ester hydrolase to release retinol, and after absorption, dietary carotenoids can be cleaved and eventually metabolized into retinol \(^{138,275}\). Subsequently, inside the enterocytes, retinol is re-esterified into retinyl esters by the action of either LRAT or DGAT1, and packaged into chylomicrons for delivery to other tissues \(^{275,276}\). Similar to dietary FAs and MGs, it has been hypothesized the intracellular lipid binding proteins are necessary for the efficient uptake and trafficking of dietary retinol \(^{11,127,138}\).

Proximal intestinal enterocytes express multiple FABPs, including IFABP, LFABP, and CRBP2. In humans, IFABP is less abundant than LFABP \(^{135,136}\), however mice express similar levels of LFABP and IFABP within the small intestinal mucosa \(^{135–137}\). We have recently found that, as with the chow fed mice, HF fed IFABP\(^{-/-}\) mice do not have a compensatory increase in LFABP gene expression or protein abundance. Additionally, no change in the gene expression of the distal small intestinal FABP, ileal-FABP (ILBP; FABP6) was observed. However, the expression of CRBP2, the other major intestinal FABP, family member had not previously been assessed.

Since no changes were observed when assessing the expression of other FABP members in the intestinal mucosa, it was initially expected that the ablation of IFABP might induce a compensatory increase in CRBP2 gene expression, or no change in expression at all. Surprisingly, HF fed IFABP\(^{-/-}\) mice were found to have a 95% reduction in CRBP2 gene expression. With such a dramatic reduction in expression observed, it was hypothesized that the expression of other vitamin A-related genes might be perturbed as well in our HF fed IFABP\(^{-/-}\) mice. Indeed, numerous alterations were observed. Of note, the expression of LRAT was found to be ~40% higher in HF fed IFABP\(^{-/-}\) mice, while the expression of RARβ was ~74% lower. In the intestine, LRAT is
responsible converting dietary retinol back into retinyl ester, though it is important to note that this process requires retinol that is bound to CRBP2. Dietary retinol can also be converted into retinyl esters independent of CRBP2/LRAT through DGAT1, though this pathway does not seem to be the predominant one under normal physiological conditions. RARβ is an important transcription factor that is able to influence an array of physiological processes, including cell growth and differentiation. Additionally, RARβ is transcriptionally regulated by retinoic acid, with lower expression being associated with lower retinoic acid levels.

As mentioned above (see Chapter 3) IFABP-/- mice have profound alterations in intestinal morphology and structure, displaying reduced average villus height, reduced goblet cell and Paneth cell densities, and altered expression of TJ-related genes. These changes were also accompanied by an altered barrier phenotype, with IFABP-/- mice having increased intestinal permeability relative to WT mice. In the intestine, it has been demonstrated that retinoic acid is able to improve intestinal barrier function through activation of RARβ. It has also been shown that vitamin A deficiency can impair the production of mucins, the main glycoprotein component that is produced by goblet cells that also acts to strengthen the intestinal barrier. Since the HF fed IFABP mice appear to have reduced RARβ, it is likely that retinoic acid signaling in the small intestine is reduced, leading to alterations in small intestinal structure which may contribute to the observed increased intestinal permeability.

As mentioned above, the gene expression of CRBP2 was exceptionally low in HF IFABP-/- mice. However, when CRBP2 protein abundance was assessed it was found that IFABP-/- and WT mice had similar abundance. This observation was surprising, since historically members of the FABP family have been shown to be regulated transcriptionally, with changes in gene expression being highly correlated with similar directional changes in protein abundance. Specifically, this transcriptional/translational pattern has been shown to occur not only for FA-binding members of the FABP family, but also with both CRBP1 and CRBP2 in various tissues.
Such a large discrepancy between message and protein in the IFABP−/− mice suggests some alteration in either mRNA and/or protein stability, and may imply that the regulation of FABPs at the level of gene expression and protein abundance may need to be reassessed under different physiological conditions.

How might the ablation of one intestinal FABP alter the gene expression of another intestinal FABP without inducing changes in the amount of protein present? It has been hypothesized that members of the FABP family are able to act as lipid chaperones, carrying various ligands to nuclear hormone receptors, or to membrane bound receptors, thereby inducing changes in gene transcription or signal transduction. It is possible that IFABP is able to modulate the activity of a transcription factor that influences the expression of CRBP2. Without IFABP present, the proper ligand may not be able to interact with its transcription factor, leading to reduced CRBP2 expression. However, it is important to note that CRBP2 is necessary when challenged with low vitamin A diets, since CRBP2−/− mice exposed to marginal vitamin A diets results in 100% mortality per litter within 24-hours after birth. This suggest an integral role for CRBP2 in adapting to diets with varying amounts of vitamin A availability. Perhaps the retained protein abundance is compensatory, resulting in CRBP2 protein with a longer half-life. It is also possible that, if there is enhanced protein stability, that it is being induced by greater ligand availability and binding. Many members of the FABP family, including CRBP2, have been shown to have more rigid structures when bound to their ligands, while unbound FABPs have more flexible structures. Additionally, there is evidence that greater rigidity may be correlated with increased structural stability, and increased protein half-life. If there is greater ligand availability, and more CRBP2 bound to ligand, it is possible the CRBP2 present in the mucosa of IFABP−/− mice is more stable than that of WT mice. LFABP and IFABP have an overlap in some of the ligands that they bind, with both being able to bind FAs. Additionally, CRBP2 and LFABP also have an overlap of ligand binding, with both being able to bind 2-MGs (Lee et al., 2019).
Perhaps the ablation of IFABP results in increased LFABP binding to FA. To compensate for the lack of available apo-LFABP, more 2-MGs may bind to CRBP2 instead. Future studies should assess CRBP2 protein half-life in WT and IFABP−/− mice. If differences in half-life are observed, potential mechanisms of proteasomal degradation such as ubiquitination or ubiquitin-independent degradation \textsuperscript{300-302}, should also be assessed in the mucosa of WT and IFABP−/− mice. For examples, it is possible that the CRBP2 present in the mucosa of IFABP−/− mice is less prone to ubiquitination over time, resulting in a longer half-life. In addition to potential regulators of protein half-life, regulators of mRNA stability, such as micro RNAs (miRNA) should also be assessed \textsuperscript{303,304}. miRNA are small non-coding RNAs that can be found in an array of cell types, being able to silence the expression of specific target genes \textsuperscript{303,304}. The levels of specific miRNAs vary under different physiological conditions \textsuperscript{303,304}. Perhaps the low level of CRBP2 gene expression is influenced by increased binding of miRNA to critical locations on the CRBP2 gene, silencing the gene without affecting the protein that has already been translated.

Since there were a number alterations in vitamin A-related gene expression in the HF fed IFABP−/− mice, tissue and plasma retinoid status was assessed. Tissues and plasma from LF fed animals were also acquired; though the vitamin A content of the LF and HF diets are the same (4IU/g), it is important to note that the vitamin A from the HF diet is more likely to be efficiently absorbed. While no changes were found in the small intestine of either LF or HF fed mice, liver retinyl ester level was found to be higher and liver retinol was found to be lower in HF fed IFABP−/− mice, suggesting greater storage of vitamin A. Plasma retinol levels are normally tightly regulated \textsuperscript{127,305,306}, yet it was found that LF fed IFABP−/− mice have reduced plasma retinol levels. This may imply that the LF fed IFABP−/− mice are more sensitive to LF challenges when compared to their WT counterparts, resulting in marginal vitamin A deficiency. To assess this idea further, gene expression studies were performed in LF fed mice as well.
Surprisingly, like their HF fed counterparts, LF fed IFABP<sup>−/−</sup> also had ~95% reduction in CRBP2 gene expression. However, unlike HF fed IFABP<sup>−/−</sup> mice, LF fed IFABP<sup>−/−</sup> mice have a 52% reduction in LRAT gene expression. Such a drastic reduction of LRAT gene expression may suggest a reduced capacity to re-esterify dietary retinol for export in chylomicrons, which might partially explain the reduced plasma retinol levels that are observed. Aside from the reduced mRNA expression of CRBP2, the changes that were observed in HF fed IFABP<sup>−/−</sup> mice were not observed in LF fed IFABP<sup>−/−</sup> mice, and vice versa. Taken together, it is possible that the ablation of IFABP results in alterations in vitamin A-related metabolism in both HF and LF fed mice. However, it is important to note that all mice that were analyzed for this study were fasted for 16 hours. With this fasting time the circulating retinol would be indicative of use by liver stores, and not necessarily the responses induced by the intestinal processing<sup>127,138</sup>. In the future, it will be important to analyze tissue from mice that have either recently fed, or have been gavaged with retinol dissolved in oil, as this will give a better representation of intestinal handling of a vitamin A challenge. Additionally, CRBP2 protein abundance in LF fed IFABP<sup>−/−</sup> mice needs to be assessed to see if a similar dissociation of message and transcript is observed.

It is also important to mention that while CRBP2 has historically been described as an FABP that is only able to bind retinol and retinal<sup>127,307</sup>, we have recently demonstrated that it is able to bind MGs, such as the endocannabinoid 2-AG, as well (<i>Lee et al., 2019 Submitted</i>). As mentioned above (see Chapter 3) in addition to alteration in intestinal morphology and structure, IFABP<sup>−/−</sup> mice were also found to have greater fecal output and more rapid intestinal transit. Endocannabinoid signaling is known to influence intestinal physiology and structure, playing a role in modulating motility, proliferation, differentiation, and inflammation<sup>265,308,309</sup>. For example, it has been shown that endocannabinoids are able to inhibit intestinal motility through activation of cannabinoid receptor 1 (CBR1)<sup>227,266</sup>. It been shown that some FABPs regulate endocannabinoid levels through enhancing hydrolysis<sup>130,131</sup>. Additionally, we have recently shown that CRBP2<sup>−/−</sup>
mice have elevated mucosal levels of 2-AG, a potent CBR1 agonist (Lee et al., 2019 Submitted), suggesting that CRBP2 may play role in regulating 2-AG hydrolysis in the small intestine. We have also shown that IFABP−/− mice trended towards having lower 2-AG levels 16, which may partly explain the more rapid intestinal transit time that is observed in these mice. It is possible that the low mucosal 2-AG levels might be due to binding by CRBP2, which may direct 2-AG towards MGL for hydrolysis, thus explaining part of the whole-body phenotyping alterations observed in the IFABP−/− mice. Though hydrolysis of 2-AG through CRBP2 binding has not been definitively shown, if CRBP2 is influencing the whole-body phenotype of the IFABP−/− mice, it is possible that the influence may be a result of altered MG metabolism rather than, or in addition to, altered vitamin A metabolism.

Overall, while the expression of LFABP and LFABP protein abundance were not found to be altered in IFABP−/− mice, the gene expression of CRBP2 appears to be dramatically low despite having normal CRBP2 protein levels. IFABP−/− mice were found to have alterations in vitamin A-related gene expression and tissue retinoid content, though whether these changes are due to the actions CRBP2 remains to be determined. Further studies are required to understand not only the influence that the intestinal FABPs may have on one another, but also the transcriptional and translation regulation of FABPs in different physiological states.
Literature Cited


37. Mccauley HA. Three cheers for the goblet cell: maintaining homeostasis in mucosal epithelia. 2015;21(8). doi:10.1016/j.molmed.2015.06.003


43. Johansson ME V, Thomsson KA, Hansson GC. Proteomic Analyses of the Two Mucus Layers of the Colon Barrier Reveal That Their Main Component, the Muc2 Mucin, Is Strongly Bound to the Fcgbp Protein research articles. *J Proteome Res.* 2009;8:3549-3557.


45. CREAMER B, SHORTER RG, BAMFORTH J. The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract. *Gut.* 1961;2:110-118. doi:10.1136/gut.2.2.110


166. Ockner RK, Burnett DA, Lysenko N, Manning JA. Sex differences in long chain fatty acid utilization and fatty acid binding protein concentration in rat liver. *J Clin Invest*. 1979;64(1):172-181. doi:10.1172/JCI109437


232. Agellon LB, Li L, Luong L, Uwiera RRE. Adaptations to the loss of intestinal fatty acid binding protein in mice. 2006:159-166. doi:10.1007/s11010-005-9042-1

233. Tomas J, Brenner C, Sansonetti PJ. Biochimie Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. 2017:1-10. doi:10.1016/j.bioclie.2017.05.019


